Use of an extract of Aureobasidium pullulans alone or in combination with a C-glycoside as a cosmetic active ingredient.

Abstract

Use of an extract of Aureobasidium pullulans alone or in combination with a C-glycoside as a cosmetic active ingredient. The present invention relates to the use of a cosmetic active ingredient comprising at least one extract of yeast biomass of the species Aureobasidium pullulans, characterized in that the extract comprises at least 25% sugars, by weight of dry matter of the extract, or in a composition comprising it, as a cosmetic active ingredient.

Description

Description Title of the invention: Use of an extract of A ureobasidium pullulans alone or in combination with a C-glycoside as an active ingredient cosmetic. Technical field

[0001] = The present invention relates to the field of care of keratin materials, in par- particular anti-aging care of keratin materials, and aims in particular to improve and / or strengthen the skin's barrier function.

[0002] = By “keratin materials” within the meaning of the present invention, we mean: in particular the skin, lips and / or eyelashes, in particular the skin and / or lips, and preferably body skin including scalp skin, and / or face, and more preferentially of the face. Prior art

[0003] — We know that human skin is made up of two tissues, one superficial, the epidermis, the other deep one, the dermis.

[0004] Skin aging results from the effects on the skin of intrinsic and ex- intrinsic. During the aging process, an alteration of the structure and skin functions appear. The main clinical signs due to these changes- disorders of skin metabolism are the appearance of wrinkles and fine lines originating from loosening and loss of elasticity of tissues.

[0005] — Furthermore, intrinsic aging, which induces changes in the skin, in particular causes a slowdown in the renewal of skin cells, which which essentially results in the appearance of clinical alterations such as reduction of subcutaneous fatty tissue and the appearance of fine lines or wrinkles, and by histopathological changes such as an increase in the number and the thickness of elastic fibers, a loss of vertical fibers of the tissue membrane elastic, and the presence of large irregular fibroblasts in the cells of this tissue elastic.

[0006] … The natural human epidermis is composed mainly of three types of cells which are the keratinocytes, the vast majority, the melanocytes and the Langerhans cells. Each of these cell types contributes through its own functions to the essential role played in the body by the skin, in particular the role of protecting the body from external aggressions (climate, ultraviolet rays, tobacco, etc.), called "function barrier".

[0007] — Generally speaking, the skin is an organ which, among other things, has a function essential physical barrier that prevents the loss of water from the body inside and external factors from penetrating inside. The stratum corneum, generated by normal differentiation on healthy skin, fulfills a barrier function, which is the most important role of the epidermis. The main cell of the epidermis is the keratinocyte, which is divided into 4 layers according to the level of differentiation, and various structural proteins are expressed. The corneodesmosome is expressed on the upper part of the stratum spinosum and the granular layer, which is stored in the lamellar body and secreted outside the cells of the stratum corneum, connecting one keratinocyte to another. Lipids contained in the lamellar body of epidermal keratinocytes at the boundary of the stratum corneum and the granular layer are secreted between the keratinocytes, forming a lipid cell envelope between the keratinocytes, acting as a permeability barrier of the epidermis in the form of a "brick and mortar" structure of corneocyte and the intercellular lipid layer surrounding it. If epidermal keratinocytes reach the granular layer, they synthesize keratohyalin granules, which contain profilaggrin and loricrin. Covalent cross-linking of constituent proteins such as involucrin and loricrin requires transglutaminase (TGase), which is a calcium-dependent enzyme catalyzing the formation of an intermolecular isopeptide bond between proteins. Of the nine TGases that have been identified in humans, TGases 1, 3, and 5 are known to participate in the formation of the cornified envelopes. Both TGases 1 and 3 are activated by limited proteolysis during keratinocyte differentiation. These enzymes cooperatively contribute to the sequential cross-linking of substrates. If the differentiation of epidermal keratinocytes is abnormal, it will lead to defects in the skin barrier function and skin dehydration, compromised skin. Tight junctions are of particular interest because they are located at the center of this complex barrier system in the outermost viable layer—the stratum granulosum of the interfollicular epidermis and the companion cell layer of the hair follicle—and because they can respond very rapidly to stimuli. The tight junction is a critically important organelle for the development and function of most vertebrate organ systems, as it allows epithelia and endothelia to create compositionally distinct fluid compartments. The tight junction forms a continuous permeability barrier between adjacent cells that regulates the flow of molecules across the paracellular space. It forms the closest contact known in nature between adjacent cells, so close, in fact, that it was once thought to be a fusion between the layers external layers of adjacent bilayers. We now know that it does not constitute an absolute seal, but rather contains discrete ion-selective pores through the extracellular portion of the junction. The extracellular portion of the tight junction must perform two main tasks: form extremely tight intercellular adhesions that close a region of the extracellular space and create regulatable pores for selective molecular sieving. In the prior art, the yeast Aureobasidium pullulans is essentially used to ferment animal or plant organic matter or to produce a particular polysaccharide, pullulan. Cosmetic compositions comprising a supernatant of A. pullulans culture or plant extracts fermented by A. pullulans are also known, but no teaching describes the use of an A. pullulans extract containing at least 25% sugars according to the present invention, in particular for an anti-aging effect and / or an effect of improving and / or reinforcing the barrier function of the skin. The applicant has discovered, very surprisingly, that the use of biomass, and more particularly an extract of yeast biomass of the species Aureobasidium pullulans, in particular as identified in the microbiota of rose bushes cultivated on the Valensol plateau in France, is of major interest as a cosmetic active ingredient, more particularly in the field of care of keratin materials, in particular to combat the signs of skin aging and to improve and / or strengthen the skin's barrier function. The applicant thus discovered, very surprisingly, that a combination comprising at least one extract of yeast biomass from the species Aureobasidium pullulans and at least one C-glycoside makes it possible to effectively combat the signs of skin aging and to improve and / or strengthen the skin's barrier function. It has thus been demonstrated, as illustrated in the examples which follow, an effectiveness of this extract of the yeast biomass of the species Aureobasidium pullulans alone on the one hand and in association with C- beta-Dxylopyranoside-2-hydroxy-propane: - on the aging of cells in the epidermal compartment, - on the migration of aged keratinocytes, - on tight junctions, and - on the differentiation of keratinocytes, which had never been described before. These efficacies support a strengthening of the skin barrier. This reinforced skin barrier contributes to the quality of the skin surface for radiance, even skin tone and smooth, soft skin. This extract of yeast biomass of the species Aureobasidium pullulans and this combination also find their application in compositions, preferably cosmetic, intended to prevent and / or treat the signs of skin aging; preferably to prevent and / or treat the cutaneous signs linked to skin presenting an alteration of its viscoelastic or biomechanical properties, skin presenting an alteration in the cohesion of its tissues, thinned skin, wrinkled skin, and / or skin presenting an alteration of its surface appearance. Said extract and said combination are preferably used topically. This extract of yeast biomass from the species Aureobasidium pullulans and this association can more specifically help to maintain and / or restore the properties of extensibility, tone, firmness, suppleness, density and / or elasticity of the skin. Finally, the formulation of environmentally friendly cosmetic products is becoming an important issue in order to satisfy new consumer expectations, in particular those for natural and / or eco-designed products, i.e. those whose design and development take environmental impacts into account. It is therefore common to seek to replace synthetic or environmentally harmful compounds present in cosmetic compositions with natural and / or naturally derived ingredients. Statement of the invention There therefore remains a need for cosmetic active ingredients, natural and / or of natural origin, which can be used in cosmetic compositions, alone or in combination with other cosmetic active ingredients, in particular to combat skin aging, in particular to improve and / or strengthen the skin's barrier function. There also remains a need to have compositions compatible with current consumer requirements, particularly from an environmental point of view. The present invention aims precisely to meet all or part of these needs. Summary of the invention Thus, according to one of its aspects, the invention proposes the use of a cosmetic active ingredient comprising at least one extract of the yeast biomass of the species Aureobasidium pullulans, characterized in that the extract comprises at least 25% of sugars, by weight of dry matter of the extract, or in a composition comprising it, as a cosmetic active ingredient. According to another of its aspects, the invention provides a composition, in particular cosmetic, non-therapeutic, comprising at least one cosmetic active ingredient comprising at least one extract of the yeast biomass of the species Aureobasidium pullulans, in particular as defined below and at least one C-glycoside, in particular as defined below, in particular present in a mass ratio as defined below. A composition according to the invention is in particular used to prevent and / or treat the signs of skin aging and / or to strengthen and / or improve the skin barrier function. Finally, according to another of its aspects, the invention provides a non-therapeutic cosmetic process for keratin materials comprising at least one step of applying to said keratin materials, preferably to the skin, a composition as defined above and detailed below. Cosmetic procedures for the care of keratinous materials, particularly the skin, are non-therapeutic. Thus, the present application also relates to the use of a composition according to the invention in order to combat the signs of skin aging and / or to strengthen and / or improve the skin barrier function. By "biomechanical properties of the skin" we mean here the properties of extensibility, tone, firmness, suppleness and / or elasticity of the skin. By "cutaneous signs of aging" we mean any change in the external appearance of the skin due to aging, whether chronobiological and / or extrinsic, in particular photoinduced or hormonal; among these signs, we can distinguish: - wrinkled skin, which is notably manifested by the appearance of wrinkles and / or fine lines; - skin with an alteration of its viscoelastic or biomechanical properties, or skin with a lack of elasticity and / or extensibility and / or firmness and / or suppleness and / or tone, which results in particular in withered, soft, sagging or sagging skin; - skin showing an alteration in the cohesion of its tissues; - thinned skin; and - skin showing an alteration in its surface appearance, which is reflected in particular by an alteration in the texture of the skin, for example roughness. For the purposes of the invention, “Aureobasidium pullulans” means any yeast of the Dothioraceae family, of the genus Aureobasidium and of the species Aureobasidium pullulans. Other characteristics, variants and advantages of the compositions in accordance with the invention will become more apparent upon reading the description and examples which follow. Detailed description Aureobasidium pullulans extract The yeast Aureobasidium pullulans, also known as black yeast, is ubiquitous, polyextremotolerant, and occurs either as a filamentous fungus or in unicellular form. A. pullulans is well known as a natural epiphyte of many plant species, such as apples and grapes. For several years, it has been used in biotechnology for the production of several enzymes or in the fight against certain plant diseases, such as apple disease. Also, the cosmetic active ingredient in accordance with the present invention comprises at least one extract derived from the biomass of the yeast of the species Aureobasidium pullulans, comprising at least 25% of sugars, by weight of dry matter of the extract. Advantageously, the yeast Aureobasidium pullulans can be taken from rose bushes, preferably grown on the Valensol plateau (France), more preferably the yeast is taken from the flowers, and / or the thorns and / or the roots of Rosa sp. Preferably, Aureobasidium pullulans is isolated from roses (Rosa sp.). The genus Rosa includes more than 200 species among which we can cite Rosa alba, Rosa alpina, Rosa canina, Rosa cinnamonea, Rosa gallica, Rosa repens, Rosa rubrifolia, Rosa rubiginosa, Rosa sempervirens, Rosa spinosissima, Rosa Stylosa, Rosa tomentosa, or even Rosa villosa, Rosa floribunda. More preferably, Aureobasidium pullulans is isolated from a hybrid rose, such as the rose of the species Rosa floribunda, even better a hybrid rose of the variety Rosa floribunda, delflobla, notably commercially available under the trade name Rose Lancôme® from the company DELBARD (France). The variety Rosa floribunda, delflobla is also described in document US2020 / 0178431. In a preferred embodiment, the Aureobasidium pullulans yeast according to the present invention is derived from a strain registered in a yeast collection (CIRM), under number CLIB 2138, on January 13, 2021. For the purposes of the invention, the term “Aureobasidium pullulans extract” means an extract comprising at least one set of molecules, preferably an extract of the biomass of the yeast Aureobasidium pullulans comprising at least sugars representing at least 25% by weight of dry matter of the total weight of the extract, obtained from any extraction process well known to those skilled in the art, for example by induced autolysis, sonication, homogenization, chemical hydrolysis, or enzymatic hydrolysis. Such extraction processes are described in the Varelas publications V. et al, Drug Test Anal. 2016 Jan and Du L. et al. Molecules. 2020 Jan 23. The extract in accordance with the invention is not an extract of the culture supernatant of Aureobasidium pullulans. For the purposes of the invention, the term “yeast culture supernatant extract” means an extract which is not an extract of the Aureobasidium pullulans culture biomass. According to one embodiment, the yeast Aureobasidium pullulans being ubiquitous, it can be present on several plant species. Preferably the yeast Aureobasidium pullulans is isolated from rose bushes, more preferably from the flowers, and / or the thorns and / or the roots of Rosa sp. The Aureobasidium pullulans biomass is produced in particular from the yeast previously obtained. This step is carried out according to the yeast culture method in a medium adapted to their development, for example a suitable culture medium, in a conventional manner for those skilled in the art. Once the biomass is obtained, an extraction step is carried out in order to obtain the active molecules, preferably an extraction of the sugars. The extract according to the invention comprises at least 25% of sugars by weight of dry matter of the extract. The extract according to the invention may also comprise peptides and mineral ash. Thus, the extract in accordance with the invention comprises sugars, these representing at least 25% of the extract, by weight of dry matter of the extract. Preferably, the extract in accordance with the invention comprises at least 45% of sugars, by weight of dry matter of the extract. The total sugar content in said cosmetic active ingredient can be determined by the DUBOIS method (Dubois M. et al, Analytical chemistry, 28, 3, 350-356, 1956). The total sugar content in the cosmetic active ingredient in accordance with the invention is expressed as a percentage relative to the dry matter. The size of the sugars present in the extract can be characterized by HPLC / RI chromatography. They can be in the form of monosaccharides or in the form of oligosaccharides, preferably oligosaccharides have a molar mass less than 1800Da. Particularly preferably, oligosaccharides are the majority within the extract according to the present invention. Finally, according to a particularly preferred embodiment, the sugars of the extract are composed of at least 80% oligosaccharides, by weight of dry matter of the sugars. Preferably, the oligosaccharides in the extract are alpha-linked glucose oligosaccharides and / or beta-linked glucose oligosaccharides. Alpha-linked glucose oligosaccharides are oligomers consisting of D-glucose linked by alpha bonds. These oligosaccharides present in the active ingredient cosmetic in accordance with the invention may have a degree of polymerization (DP) of between 2 and 10 units. Furthermore, these oligosaccharides can have a molar mass of less than 1800 Daltons. Preferably, they represent between 1.5 and 4 g / L. Beta-linked glucose oligosaccharides are oligosaccharides, consisting of D-glucose linked by beta bonds. These oligosaccharides present in the cosmetic active ingredient in accordance with the invention have a degree of polymerization of between 2 and 10 units, and have a molar mass of less than 1800 Daltons. Preferably, they represent between 1.5 and 4 g / L. Also, the cosmetic active ingredient in accordance with the invention comprises sugars with oligosaccharide structures having a degree of polymerization (DP) of less than 10, i.e. a molar mass of less than 1800 Daltons. The extract according to the invention also comprises peptides. Preferably, these represent at least 30% by weight of dry matter of the extract. The peptide content can be determined by measuring the total nitrogen content according to the KJELDHAL method (reference: Official method of analysis of the AOC, 12th ed. W Horwitz, ED, New York, 15-60, 1975). The peptides have a molar mass of less than 2000Da. The distribution and molar mass of the peptides can be determined by size exclusion FPLC (Fast Protein Liquid Chromatography), the quantity of each peptide fraction is determined by spectrophotometric assay according to the Lowry method (Lowry et al., Protein measurement with the Folin reagent, J. Biol. Chem., 193, 265-275, 1951). When the extract according to the invention comprises mineral ash, the ash content is preferably between 8 and 18% by weight relative to the dry matter of the extract, even more preferably between 10 and 15%. The crude ash content can be determined by weighing the residues resulting from the incineration of the samples at 550°C in a muffle furnace. The nature of the minerals contained in the ash can be determined by optical emission spectrometry (ICP / OES). The determination of the chloride ions contained in the ash is carried out by titration with silver nitrate. Preferably, the mineral ash contained in the extract according to the invention comprises calcium, phosphorus, chloride ions, magnesium, sulfur and sodium. The dry matter content of the extract can be determined by weighing the residues resulting from drying the extract according to the invention at 105°C in an oven until a constant weight is obtained. Preferably, the extract according to the invention in liquid form has a dry matter content of: 10 g / L to 40 g / L, even more preferably of 17 g / L to 26 g / L. The cosmetic active ingredient in accordance with the invention may be in the form liquid or solid form. When it is in liquid form, the cosmetic active ingredient in accordance with the invention is preferably the extract as described above as such. It is in the form of a clear liquid, very light yellow in color and having a weak odor. It may, however, be more colored and / or be decolorized by any process known to those skilled in the art. The cosmetic active ingredient may also be combined with stabilizing agents or preservatives. When it is in solid form, the cosmetic active ingredient in accordance with the invention is preferably constituted by the extract of Aureobasidium pullulans as previously described and by a carrier chosen from maltodextrin, gum arabic, soy lecithin or isomalt. According to a particularly suitable embodiment, the extract represents at least 10% by weight of the cosmetic active ingredient and the carrier at most 90% by weight of the cosmetic active ingredient. In the case of a solid form in which the cosmetic active ingredient is associated with a carrier, the protein, sugar and ash contents in the cosmetic active ingredient are modified, the carrier generally being made up mainly of sugars. The cosmetic active ingredient in accordance with the invention may optionally be integrated, for use according to the present invention, into a cosmetic composition, in particular a composition comprising at least 0.0005% by weight of dry matter of said cosmetic active ingredient. In particular, the composition is in a form suitable for topical application such as a cream or a lotion. Extraction process The extract constituting or contained in the cosmetic active ingredient in accordance with the invention may be obtained by any process comprising at least one step of extracting the biomass of the Aureobasidium pullulans yeast. The extraction of the yeast biomass does not consist of recovering the supernatant of the yeast culture. Prior to the process for obtaining the extract as such, it is appropriate to produce the biomass of Aureobasidium pullulans. This step is carried out according to the method of culturing the yeasts in a medium adapted to their development, for example a suitable culture medium, in a conventional manner for those skilled in the art. Once the biomass has been obtained, an extraction step can be carried out in order to obtain the active molecules, preferably sugars. The extraction step can be carried out by any means known to those skilled in the art, for example by induced autolysis, sonication, homogenization, enzymatic lysis, chemical hydrolysis, enzymatic hydrolysis. For example, the cosmetic active ingredient in accordance with the invention can be obtained by the implementation of the following steps: the cultivation of Aureobasidium pullulans biomass in a culture medium, preferably a suitable culture medium, b. solubilization of at least 50g / L of Aureobasidium pullulans biomass in the water, c. extraction, preferably extraction of sugars, d. heat treatment, e separation of the soluble and insoluble phase, and recovery of the soluble phase, £ purification by molecular sorting, and possibly decolorization and deodorization- rization, and g. possibly concentration and sterilizing filtration. The separation of the soluble and insoluble phases is carried out by any means known to those skilled in the art, for example by centrifugation, filtration or decantation. Preferably, the separation of the soluble and insoluble phases is carried out to recover the soluble phase containing, among other things, soluble sugars, such as oligosaccharides. Optionally, the process includes a filtration step after recovery of the soluble phase to remove particles still in suspension. Thus, this filtration step allows the purification of the recovered soluble phase and is carried out in order to remove high molecular weight molecules. The product obtained at this stage may optionally be further concentrated and / or purified, preferably by successive ultrafiltration stages through filters of different porosity, retaining the filtrates at each stage and / or by a chromatographic type method. The product obtained after filtration, before or after concentration and sterilizing filtration, is an extract of Aureobasidium pullulans, and constitutes a first form of the cosmetic active ingredient in accordance with the invention, then presented in liquid form. The extract obtained can then be dried and combined or not with a support, to be presented in solid form. This phase can be carried out by implementing the following steps: an atomizing medium, preferably maltodextrin, is added in Aureobasidium pullulans extract, not more than 90% (mass / volume); this solution is then concentrated under vacuum; elimination of any bacteria that may be present is carried out by thermal treatment ; atomization produces a powder. The steps of the processes described above, taken individually, are common in the field of active ingredient extraction from natural raw materials and man. of the profession is able to adjust the reaction parameters on the basis of his general knowledge. Use and cosmetic process according to the invention According to one embodiment of the invention, the use according to the invention is characterized in that it is intended to prevent and / or treat the signs of skin aging and / or to strengthen and / or improve the skin barrier function. According to another embodiment of the invention, the use according to the invention is characterized in that it is intended for hydrating the skin and / or for improving the quality of the surface of the skin, in particular for improving the radiance of the skin and / or for improving the homogeneity of the complexion and / or for reducing the microreliefs of the skin. According to yet another embodiment, the use is characterized in that said cosmetic active ingredient is in association with at least one C-glycoside, in particular as defined below. As mentioned previously, the present invention relates to a cosmetic process for keratin materials comprising at least one step of applying to said keratin materials, preferably to the skin, a composition according to the invention, as detailed below. According to a particular embodiment, the cosmetic process is characterized in that it is intended to prevent and / or treat the signs of skin aging and / or to strengthen and / or improve the skin barrier function. According to a particular embodiment, the cosmetic process is characterized in that it is intended for hydrating the skin and / or improving the quality of the surface of the skin, in particular improving the radiance of the skin and / or improving the homogeneity of the complexion and / or reducing the microreliefs of the skin. The cosmetic process and the use according to the invention are implemented by administering topically a composition comprising a cosmetic active ingredient comprising at least one extract in accordance with the invention, optionally in association with a C-glycoside. Topical administration consists of the external application to the skin of such a cosmetic composition according to the usual techniques for using these compositions. By way of illustration, the cosmetic process or use according to the invention may be implemented by topical application, for example daily, of such a composition, which may for example be formulated in the form of a cream, gel, serum, lotion, emulsion, cleansing milk, stick or after-sun composition, preferably in the form of an emulsion. According to one embodiment, the application is repeated for example 1 to 2 times daily over one day or more and generally over a prolonged period of at least 4, or even 4 to 15 weeks, with, where appropriate, one or more periods of interruption. According to another embodiment, the application is daily (once a day) and generally over a prolonged period of at least 4, or even 4 to 15 weeks, with one or more periods of interruption where appropriate. Indeed, as is clear from the examples given below, it has been demonstrated that the extract in accordance with the present invention makes it possible to obtain an improved effect on the pathways of aging metabolism (example 4) or even an improved effect in the stimulation of the migration of aged keratinocytes and therefore an anti-aging efficacy (example 5). Furthermore, as also emerges from the examples appearing below, the extract in accordance with the present invention was tested, alone or in association with a C-glycoside, in particular on epidermal markers, in particular filaggrin, loricrin, claudin-1, ZO-1, CK10, TGK (coded by the TGM1 gene) and involucrin (examples 6 and 8). In particular, Transglutaminase K (TGK), filaggrin and involucrin, CK10 and loricrin are markers of the differentiation of keratinocytes in the stratum corneum. Filaggrin and TGK are also markers of the skin barrier function. Claudin-1, occludin, and ZO-1 (zonula occludens-1) are markers of tight junctions. A composition comprising the extract in accordance with the present invention, alone or in combination with a C-glycoside, as described previously, has moreover been clinically tested and has demonstrated beneficial effects on the skin, in particular on the barrier function and the microrelief (example 7). The extract in accordance with the present invention, alone or in association with a C-glycoside, thus makes it possible to stimulate the production of tight junction proteins in the skin, inducing better intercellular cohesion and to stimulate the production of proteins involved in keratinocyte differentiation in the skin. cosmetic composition comprising the combination of an extract of aureobasidium pullulans and a C-glycoside C-glycoside The C-glycoside (or C-glycoside derivative) in accordance with the invention is preferably of the following general formula (I): [Chem.1] gr ETS (D in which: - R represents: - a linear alkyl radical, saturated in C1 to C20, preferably in C1 to C10, or unsaturated in C2 to C20, preferably in C3 to C10, or a branched or cyclic alkyl radical, saturated or unsaturated, in C3 to C20, preferably in C4 to C10; - a hydrofluoro- or perfluoro-alkyl radical, linear saturated in C1 to C20, preferably in C2 to C10, or unsaturated in C2 to C20, preferably in C2 to C10, or branched or cyclic, saturated or unsaturated, in C3 to C20, preferably in C4 to C10; - a phenyl or benzyl radical, - the hydrocarbon chain constituting said radicals may, where appropriate, be interrupted by 1, 2, 3 or more heteroatoms chosen from: oxygen, sulfur, nitrogen, silicon, halogen atom, - and which may optionally be substituted by at least one radical chosen from: OR4, -SR4, -NR4R5, -COOR4, -CONHR4, -CN, a hydrofluoro- or perfluoro-alkyl radical, C1 to C6, and / or a cycloalkyl radical C3 to C8, and / or at least one cycloalkyl, aryl, heterocyclic radical, C5 to C18, optionally substituted, - with R4 and R5 being able to represent, independently of one another, a hydrogen atom, or a linear alkyl, perfluoroalkyl or hydrofluoroalkyl radical, saturated in C1 to C30, preferably in C3 to C12, or unsaturated in C2 to C30, preferably in C3 to C12, or branched or cyclic, saturated or unsaturated, in C3 to C30, preferably in C4 to C12; or a C6 to C10 aryl radical, - X represents a radical chosen from -CO-, -CH(OH)-, -CH(NHz)-, and preferably a -CH(OH)- group; - S represents a monosaccharide or a polysaccharide comprising up to 20 sugar units, preferably up to 6 sugar units, in pyranose and / or furanose form and of L and / or D series, said mono- or polysaccharide possibly being substituted by a hydroxyl group which must be free, and optionally one or more amine function(s) which may be protected, and - the S-CHz-X bond represents a C-anomeric bond, which can be A or PB, as well as their physiologically acceptable salts, their solvates such as hydrates and their isomers. In the context of the present invention, by "halogen" is meant chlorine, fluorine, bromine or iodine. The term "aryl" refers to an aromatic ring such as phenyl, optionally substituted by one or more C1-C4 alkyl radicals. The term “C3-C8 cycloalkyl” means an aliphatic ring having 3 to 8 carbon atoms, including for example cyclopropyl, cyclopentyl and cyclohexyl. Among the alkyl groups suitable for implementing the invention, mention may in particular be made of methyl, ethyl, isopropyl, n-propyl, n-butyl, t-butyl, isobutyl, sec-butyl, pentyl, n-hexyl, cyclopropyl, cyclopentyl, cyclohexyl, and allyl groups. A C-glycoside may correspond to formula (I) for which $ may represent a monosaccharide or a polysaccharide containing up to 6 sugar units, in pyranose and / or furanose form and of L and / or D series, said mono- or polysaccharide having at least one hydroxyl function which must be free and / or possibly one or more amine functions which must be protected, X and R otherwise retaining all of the definitions previously given. Advantageously, a monosaccharide in accordance with the invention may be chosen from D-glucose, D-galactose, D-mannose, D-xylose, D-lyxose, L-fucose, L-arabinose, L-rhamnose, D-glucuronic acid, D-galacturonic acid, D-iduronic acid, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine and advantageously denotes D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, and more preferably D-xylose. Advantageously, a polysaccharide in accordance with the invention containing up to 6 sugar units may be chosen from D-maltose, D-lactose, D-cellobiose, D-maltotriose, a disaccharide combining a uronic acid chosen from D-iduronic acid or D-glucuronic acid with a hexosamine chosen from D-galactosamine, D-glucosamine, N-acetyl-D-galactosamine, N-acetyl-D-glucosamine, an oligosaccharide containing at least one xylose which may be advantageously chosen from xylobiose, methyl-B-xylobioside, xylotriose, xylotetraose, xylopentaose and xylohexaose and in particular xylobiose which is composed of two xylose molecules linked by a 1-4 bond. More preferably, S can represent a monosaccharide chosen from D-glucose, D-xylose, L-fucose, D-galactose, D-maltose, even better D-xylose. Advantageously, it is possible to use a C-glycoside corresponding to formula (I) for which R represents a linear alkyl radical, saturated in C1 to C20, preferably in C1 to C10, or unsaturated in C2 to C20, preferably in C3 to C10, or a branched or cyclic alkyl radical, saturated or unsaturated, in C3 to C20; preferably in C4 to C10, and optionally substituted as described above, S and X moreover retaining all of the definitions previously given. More preferably, R may denote a linear C1-C4, preferably C1-C2, radical, optionally substituted by —OH, -COOH or -COOR”'2, R°'2 being a saturated C1-C4 alkyl radical, in particular methyl. Even better, R may denote an unsubstituted linear C1-C4, preferably C1-C2, alkyl radical, such as methyl. According to a preferred embodiment, among the C-glycosides of formula (I), those are used for which: R represents a linear, saturated C1 to C20, preferably C1 to C10, or unsaturated C2 to C20, preferably C3 to C10, alkyl radical or a branched or cyclic, saturated or unsaturated, C3 to C20, preferably C4 to C10, alkyl radical and optionally substituted as described above; S represents a monosaccharide as described above, preferably D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, more preferably D-xylose; X represents a radical chosen from -CO-, -CH(OH)-, -CH(NRA2)-, preferably a -CH(OH)- group. According to a preferred embodiment, a C-glycoside of formula (I) is used for which: R denotes a linear C1-C4 radical, preferably C1-C3, optionally substituted by -OH, -COOH or -COOR”'2, R°°2 being a saturated C1-C4 alkyl radical, such as methyl; S represents a monosaccharide as described above, preferably D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, more preferably D-xylose; X represents a radical chosen from -CO-, -CH(OH)-, -CH(NR2)-, preferably a -CH(OH)- group. According to a preferred embodiment, a C-glycoside of formula (I) can be used for which: R denotes an unsubstituted linear C1-C4, preferably C1-C2, alkyl radical, such as methyl; S represents a monosaccharide as described above, preferably D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, more preferably D-xylose; X represents a group chosen from -CO-, -CH(OH)-, -CH(NH2)- and -CH(OH)-, preferably a -CH(OH)- group. Acceptable salts for non-therapeutic use of the compounds described herein include conventional non-toxic salts of said compounds such as those formed from organic or inorganic acids. Examples include salts of mineral acids, such as sulfuric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, boric acid. Mention may also be made of salts of organic acids, which may contain one or more carboxylic, sulfonic or phosphonic acid groups. These may be linear, branched or cyclic aliphatic acids or aromatic acids. These acids may also contain one or more heteroatoms chosen from O and N, for example in the form of hydroxyl groups. Mention may in particular be made of propionic acid, acetic acid, terephthalic acid, citric acid and tartaric acid. When the compound of formula ([) comprises an acid group, the neutralization of the acid group(s) may be carried out by a mineral base, such as LIOH, NaOH, KOH, Ca(OH)2, NH40H, Mg(OH)2 or Zn(OH)2; or by an organic base such as a primary, secondary or tertiary alkylamine, for example triethylamine or butylamine. This primary, secondary or tertiary alkylamine may comprise one or more nitrogen and / or oxygen atoms and may therefore comprise, for example, one or more alcohol functions; mention may in particular be made of amino-2-methyl-2-propanol, triethanolamine, dimethylamino-2-propanol, 2-amino-2-(hydroxymethyl)-1,3-propanediol. Other examples include lysine or 3-(dimethylamino)propylamine. Acceptable solvates for the compounds described in the present invention include conventional solvates such as those formed during the last step of preparation of said compounds due to the presence of solvents. For example, solvates due to the presence of water or linear or branched alcohols such as ethanol or isopropanol may be mentioned. Preferably, the C-glycosides of formula (I), used in accordance with the invention, are chosen from: 1. CPD-xylopyranoside-n-propane-2-one; 2. CaD-xylopyranoside-n-propane-2-one; 3. 1-[2-(3-hydroxy-propylamino)-propyl]- C- B -D-xylopyranose; 4. 1-[2-(3-hydroxy-propylamino)-propyl]-CaD-xylopyranose; 5. CBD-xylopyranoside-2-hydroxy-propane; 6. CaD-xylopyranoside-2-hydroxy-propane; 7. CBD-xylopyranoside-2-amino-propane; 8. CaD-xylopyranoside-2-amino-propane; 9. CBD-xylopyranoside-2-phenylamino-propane; 10. CaD-xylopyranoside-2-phenylamino-propane; 11. 3-methyl-4-(CBD-xylopyranoside)-butyric acid ethyl ester; 12. 3-methyl-4-(CaD-xylopyranoside)-butyric acid ethyl ester; 13. 6-(CBD-xylopyranoside)-5-keto-hexanoic acid; 14. 6-(CaD-xylopyranoside)-5-keto-hexanoic acid; 15. 6-{CPD-xylopyranoside)-5-hydroxy-hexanoic acid; 16. 6-{CaD-xylopyranoside)-5-hydroxy-hexanoic acid; 17. 6-(CPD-xylopyranoside)-5-amino-hexanoic acid; 18. 6-(CaD-xylopyranoside)-5-amino-hexanoic acid; 19. 6-(CBD-xylopyranoside)-5-phenylamino-hexanoic acid; 20. 6-(CaD-xylopyranoside)-5-phenylamino-hexanoic acid; 21. 1-(CBD-xylopyranoside)-hexane-2,6-diol; 22. 1-(CaD-xylopyranoside)-hexane-2,6-diol; 23. 5-(CBD-xylopyranoside)-4-keto-pentanoic acid; 24. 5-(CaD-xylopyranoside)-4-keto-pentanoic acid; 25. 5-(CBD-xylopyranoside)-4-hydroxy-pentanoic acid; 26. 5-(CaD-xylopyranoside)-4-hydroxy-pentanoic acid; 27. 5-(CBD-xylopyranoside)-4-amino-pentanoic acid; 28. 5-(CaD-xylopyranoside)-4-amino-pentanoic acid; 29. 5-(CBD-xylopyranoside)-4-phenylamino-pentanoic acid; 30. 5-(CaD-xylopyranoside)-4-phenylamino-pentanoic acid; 31. 1-(CfD-xylopyranoside)-pentane-2,5-diol; 32. 1-(CaD-xylopyranoside)-pentan-2,5-diol; 33. 1-(CPD-fucopyranoside)-propane-2-one; 34, 1-(CaD-fucopyranoside)-propane-2-one; 35. 1-(CBL-fucopyranoside)-propane-2-one; 36. 1-(CaL-fucopyranoside)-propane-2-one; 37. 1-(CBD-fucopyranoside)-2-hydroxy-propane; 38. 1-(CaD-fucopyranoside)-2-hydroxy-propane; 39. 1-(CBL-fucopyranoside)-2-hydroxy-propane; 40. 1-(CaL-fucopyranoside)-2-hydroxy-propane; 41. 1-(CBD-fucopyranoside)-2-amino-propane; 42. 1-(CaD-fucopyranoside)-2-amino-propane; 43. 1-(CBL-fucopyranoside)-2-amino-propane; 44, 1-(CaL-fucopyranoside)-2-amino-propane; 45. 1-(CBD-fucopyranoside)-2-phenylamino-propane; 46. ​​1-(CaD-lucopyranoside)-2-phenylamino-propane; 47. 1-(CBL-fucopyranoside)-2-phenylamino-propane; 48. 1-(CaL-fucopyranoside)-2-phenylamino-propane; 49. 3-methyl-4-(CBD-fucopyranoside)-butyric acid ethyl ester; 50. 3-methyl-4-(CaD-fucopyranoside)-butyric acid ethyl ester; 51. 3-methyl-4-(CBL-fucopyranoside)-butyric acid ethyl ester; 52. 3-methyl-4-(CaL-fucopyranoside)-butyric acid ethyl ester; 53. 6-(CBD-fucopyranoside)-5-keto-hexanoic acid; 54. 6-(CaD-fucopyranoside)-5-keto-hexanoic acid; 55. 6-(CPL-fucopyranoside)-5-keto-hexanoic acid; 56. 6-(CaL-fucopyranoside)-5-keto-hexanoic acid; 57. 6-(CfD-fucopyranoside)-5-hydroxy-hexanoic acid; 58. 6-(CaD-fucopyranoside)-5-hydroxy-hexanoic acid; 59. 6-(C-fB-L-fucopyranoside)-5-hydroxy-hexanoic acid; 60. 6-(CaL-fucopyranoside)-5-hydroxy-hexanoic acid; 61. 6-(CPD-fucopyranoside)-5-amino-hexanoic acid; 62. 6-(CaD-fucopyranoside)-5-amino-hexanoic acid; 63. 6-(CPL-fucopyranoside)-5-amino-hexanoic acid; 64. 6-(CaL-fucopyranoside)-5-amino-hexanoic acid; 65. 1-(CBD-fucopyranoside)-hexane-2,6-diol; 66. 1-(CaD-fucopyranoside)-hexane-2,6-diol; 67. 1-(CBL-fucopyranoside)-hexane-2,6-diol; 68. 1-(CaL-fucopyranoside)-hexane-2,6-diol; 69. 5-(CBD-fucopyranoside)-4-keto-pentanoic acid; '70. 5-(CaD-fucopyranoside)-4-keto-pentanoic acid; 71. 5-(CBL-fucopyranoside)-hexane-2,6-diol)-4-keto-pentanoic acid; 72. 5-(CaL-fucopyranoside)-hexane-2,6-diol)-4-keto-pentanoic acid; 73. 5-(CBD-fucopyranoside)-4-hydroxy-pentanoic acid; 74, 5-(CaD-fucopyranoside)-4-hydroxy-pentanoic acid; 75. 5-(CBL-fucopyranoside)-4-hydroxy-pentanoic acid; 76. 5-(CaL-fucopyranoside)-4-hydroxy-pentanoic acid; 77. 5-(CBD-fucopyranoside)-4-amino-pentanoic acid; 78. 5-(CaD-fucopyranoside)-4-amino-pentanoic acid 79. 5-(CBL-fucopyranoside)-4-amino-pentanoic acid; 80. 5-(CaL-fucopyranoside)-4-amino-pentanoic acid; 81. 1-(CBD-fucopyranoside)-pentane-2,5-diol; 82. 1-(CaD-fucopyranoside)-pentane-2,5-diol; 83. 1-(CBL-fucopyranoside)-pentane-2,5-diol; 84, 1-(CaL-lucopyranoside)-pentane-2,5-diol; 85. 1-(CBD-glucopyranosyl)-2-hydroxy-propane; 86. 1-(CaD-glucopyranosyl)-2-hydroxy-propane; 87. 1-(C-BP-D-glucopyranosyl)-2-amino-propane; 88. 1-(CaD-glucopyranosyl)-2-amino-propane; 89. 1-(CBD-glucopyranosyl)-2-phenylamino-propane; 90. 1-(CaD-glucopyranosyl)-2-phenylamino-propane; 91. 3-methyl-4-(CBD-glucopyranosyl)-butyric acid ethyl ester; 92. 3-methyl-4-(CaD-glucopyranosyl)-butyric acid ethyl ester; 93. 6-(CBD-glucopyranosyl)-S-keto-hexanoic acid; 94. 6-(CaD-glucopyranosyl)-5-keto-hexanoic acid; 95. 6-(CBD-glucopyranosyl)-5-hydroxy-hexanoic acid; 96. 6-(CaD-glucopyranosyl)-5-hydroxy-hexanoic acid; 97. acide 6-(C-B-D-glucopyranosyl)-5-amino-hexanoique ; 98. acide 6-(C-a-D-glucopyranosyl)-5-amino-hexanoique ; 99. acide 6-(C-B-D-glucopyranosyl)-5-phénylamino-hexanoique ; 100. acide 6-(C-a-D-glucopyranosyl)-5-phénylamino-hexanoique ; 101. 1-(C-B-D-glucopyranosyl)-hexane-2,6-diol ; 102. 1-(C-a-D-glucopyranosyl)-hexane-2,6-diol ; 103. acide 6-(C-fB-D-glucopyranosyl)-5-céto-pentanoique ; 104. acide 6-(C-a-D-glucopyranosyl)-5-céto-pentanoique ; 105. acide 6-(C-f-D-glucopyranosyl)-5-hydroxy-pentanoique ; 106. acide 6-(C-a-D-glucopyranosyl)-5-hydroxy-pentanoique ; 107. acide 6-(C-B-D-glucopyranosyl)-5-amino-pentanoique ; 108. acide 6-(C-a-D-glucopyranosyl)-5-hydroxy-pentanoique ; 109. acide 6-(C-B-D-glucopyranosyl)-5-phénylamino-pentanoique ; 110. acide 6-(C-a-D-glucopyranosyl)-5-phénylamino-pentanoique ; 111. 1-(C-B-D-glucopyranosyl)-pentane-2,5-diol ; 112. 1-(CaD-glucopyranosyl)-pentan-2,5-diol; 113. 1-(CBD-galactopyranosyl)-2-hydroxy-propane; 114. 1-(Ca—D-galactopyranosyl)-2-hydroxy-propane; 115. 1-(CBD-galactopyranosyl)-2-amino-propane; 116. 1-(CaD-galactopyranosyl)-2-amino-propane; 117. 1-(CBD-galactopyranosyl)-2-phenylamino-propane; 118. 1-(CaD-galactopyranosyl)-2-phenylamino-propane; 119. 3-methyl-4-(BD-galactopyranosyl)-butyric acid ethyl ester; 120. 3-methyl-4-(aD-galactopyranosyl)-butyric acid ethyl ester; 121. 6-(CBD-galactopyranosyl)-5-keto-hexanoic acid; 122. 6-(CaD-galactopyranosyl)-5-keto-hexanoic acid; 123. 6-(C-fB-D-galactopyranosyl)-5-hydroxy-hexanoic acid; 124. 6-(CaD-galactopyranosyl)-5-hydroxy-hexanoic acid; 125. 6-(CBD-galactopyranosyl)-5-amino-hexanoic acid; 126. 6-(CaD-galactopyranosyl)-5-amino-hexanoic acid; 127. 6-(CBD-galactopyranosyl)5-phenylamino-hexanoic acid; 128. 6-(CaD-galactopyranosyl)5-phenylamino-hexanoic acid; 129. 1-(CBD-galactopyranosyl)-hexane-2,6-diol; 130. 1-(CaD-galactopyranosyl)-hexane-2,6-diol; 131. 6-(C-[BD-galactopyranosyl)-5-keto-pentanoic acid; 132. 6-(CaD-galactopyranosyl)-5-keto-pentanoic acid; 133. 6-(CfD-galactopyranosyl)-5-hydroxy-pentanoic acid; 134. 6-(CaD-galactopyranosyl)-5-hydroxy-pentanoic acid; 135. 6-(CBD-galactopyranosyl)-5-amino-pentanoic acid; 136. 6-(CaD-galactopyranosyl)-5-amino-pentanoic acid; 137. 6-(CBD-galactopyranosyl)-5-phenylamino-pentanoic acid; 138. 6-(CaD-galactopyranosyl)-5-phenylamino-pentanoic acid; 139. 1-(CBD-galactopyranosyl)-pentane-2,6-diol; 140. 1-(CaD-galactopyranosyl)-pentan-2,6-diol; 141. 1-(CBD-fucofuranosyl)-propane-2-one; 142. 1-(CaD-fucofuranosyl)-propane-2-one; 143. 1-(CBL-fucofuranosyl)-propane-2-one; 144. 1-(CaL-fucofuranosyl)-propane-2-one; 145. 3"-(acetamido-CBD-glucopyranosyl)-propan-2"-one; 146. 3'-(acetamido-CaD-glucopyranosyl)-propan-2"-one; 147. 1-(acetamido-CfD-glucopyranosyl)-2-hydroxyl-propane; 148. 1-(acetamido-CBD-glucopyranosyl)-2-amino-propane; 149. 1-(acetamido-CBD-glucopyranosyl)-2-phenylamino-propane; 150. 1-(acetamido-CaD-glucopyranosyl)-2-phenylamino-propane; 151. 3-methyl-4-(acetamido-CBD-glucopyranosyl)-butyric acid ethyl ester; 152. 3-methyl-4-(acetamido-CaD-glucopyranosyl)-butyric acid ethyl ester; 153. 6-(acetamido-C-[BD-glucopyranosyl]-5-keto-hexanoic acid; 154. 6-(acetamido-CaD-glucopyranosyl)-5-keto-hexanoic acid; 155. 6-(acetamido-CBD-glucopyranosyl)-S-hydroxy-hexanoic acid; 156. 6-(acetamido-CaD-glucopyranosyl)-5-hydroxy-hexanoic acid; 157. 6-(acetamido-CBD-glucopyranosyl)-5-amino-hexanoic acid; 158. 6-(acetamido-CaD-glucopyranosyl)-5-amino-hexanoic acid; 159. 6-(acetamido-CBD-glucopyranosyl)-5-phenylamino-hexanoic acid; 160. 6-(acetamido-CaD-glucopyranosyl)-5-phenylamino-hexanoic acid; 161. 1-(acetamido-CBD-glucopyranosyl)-hexane-2,6-diol; 162. 1-(acetamido-CaD-glucopyranosyl)-hexane-2,6-diol; 163. 6-(acetamido-C-[-D-glucopyranosyl)-5-keto-pentanoic acid; 164. 6-(acetamido-CaD-glucopyranosyl)-5-keto-pentanoic acid; 165. 6-(acetamido-CBD-glucopyranosyl)-5-hydroxy-pentanoic acid; 166. 6-(acetamido-CaD-glucopyranosyl)-5-hydroxy-pentanoic acid; 167. 6-(acetamido-CBD-glucopyranosyl)-5-amino-pentanoic acid; 168. 6-(acetamido-CaD-glucopyranosyl)-5-amino-pentanoic acid; 169. 6-(acetamido-CBD-glucopyranosyl)-5-phenylamino-pentanoic acid; 170. 6-(acetamido-CaD-glucopyranosyl)-5-phenylamino-pentanoic acid; 171. 1-(acetamido-CBD-glucopyranosyl)-pentane-2,5-diol; 172. 1-(acetamido-CaD-glucopyranosyl)-pentan-2,5-diol. Even more preferably, the C-glycosides used in accordance with the invention are chosen from: - CBD-xylopyranoside-n-propane-2-one, - Ca-D-xylopyranoside-n-propan-2-one, - CBD-xylopyranoside-2-hydroxy-propane, - Ca-D-xylopyranoside-2-hydroxy-propane, - 1-(CBD-fucopyranoside)-propane-2-one, - la 1-(C-a-D-fucopyranoside)-propane-2-one, - la 1-(C-B-L-fucopyranoside)-propane-2-one, - la 1-(C-a-L-fucopyranoside)-propane-2-one, - le 1-(C-B-D-fucopyranoside)-2-hydroxy-propane, - le 1-(C-a-D-fucopyranoside)-2-hydroxy-propane, -le 1-(C-B-L-fucopyranoside)-2-hydroxy-propane, - le 1-(C-a-L-fucopyranoside) -2-hydroxy-propane, -le 1-(C-fB-D-Glucopyranosyl)-2-hydroxyl-propane, - le 1-(C-a-D-Glucopyranosyl)-2-hydroxyl-propane, - le 1-(C-fB-D-galactopyranosyl)-2-hydroxyl-propane, -le 1-(C-a-D-galactopyranosyl)-2-hydroxyl-propane - la 1-(C-fB-D-fucofuranosyl)-propane-2-one, - la 1-(C-a-D-fucofuranosyl)-propane-2-one - la 1-(C-fB-L-fucofuranosyl)-propane-2-one, - la 1-(C-a-L-fucofuranosyl)-propane-2-one, - le C-P-D-maltopyranoside-n-propane-2-one, - C-to-D-maltopyranoside-n-propan-2-one - CBD-maltopyranoside-2-hydroxy-propane, - C-to-D-maltopyranoside-2-hydroxy-propane, their isomers or their mixtures. Even better, the C-glycoside used in the context of the invention is C-beta-D-xylopyranoside-2-hydroxy-propane or C- alpha-D-xylopyranoside-2-hydroxy-propane, and preferably C- beta-D-xylopyranoside-2-hydroxy-propane such as that marketed under the name MEXORYL SBB® or MEXORYL SCN® by NOVEAL whose INCI name is HYDROXYPROPYL TETRAHYDROPYRANTRIOL or under the name MEXORYL SBB® which contains 35% by weight of hydroxypropyl tetrahydropyrantriol in 40% by weight of water and 25% of propylene glycol. Said C-glycoside may be present in the composition in an amount ranging from 0.001% to 10% by weight of active material relative to the total weight of the composition, preferably from 0.005% to 5% by weight of active material, more preferably from 0.01% to 4% by weight of active material relative to the total weight of the composition, even better from 0.5% to 3.5% by weight of active material relative to the total weight of the composition, such as 0.6% or 3.2% by weight of active material relative to the total weight of the composition. In a preferred embodiment, said C-glycoside may be in the composition in an amount of at least 0.01% by weight, preferably at least 0.5% by weight of active material relative to the total weight of the composition. The extract of the yeast biomass of the species Aureobasidium pullulans may be present in the composition in a content ranging from 0.0005% to 1% by weight of dry matter, preferably ranging from 0.001% to 1% by weight of dry matter, more preferably ranging from 0.005% to 0.5% by weight of dry matter, and even better ranging from 0.01% to 0.3% by weight, relative to the total weight of the composition. Preferably, the mass ratio [C-glycoside(s) / extract from the yeast biomass of the species Aureobasidium pullulans] is less than or equal to 50, more preferably the mass ratio [C-glycoside(s) / extract from the yeast biomass of the species Aureobasidium pullulans] is between 5 and 50, even better between 8 and 49, Forms of the compositions The description of the compositions can apply both to the compositions according to the invention and to the compositions in which the cosmetic active ingredient comprising the extract can be formed within the framework of the use which is the subject of the present invention. Such compositions may be in the form of cosmetic compositions for the care of keratin materials, preferably cosmetic compositions for the care of keratin materials, in particular for the body or face, preferably for the face. These compositions may constitute cleansing, protective, treatment or care creams for the face, for the hands, or for the body including the skin of the scalp, for example day creams, night creams, make-up creams, foundation creams, sun creams or hair lotions or creams for the scalp. In particular, the compositions may be in the form of anti-aging, moisturizing or photoprotection care compositions, in particular anti-aging care, for the skin of the body or face, in particular the face. The compositions can be applied to the skin by hand or using an applicator. More generally, the compositions may be characterized as containing a physiologically acceptable medium, i.e. a medium suitable for the administration of a composition topically, i.e. compatible with the skin. According to the invention, a physiologically acceptable medium is preferably a cosmetically acceptable medium, i.e. without odor or unpleasant appearance, and which is perfectly compatible with the topical administration route, i.e. which has a pleasant color and feel and does not generate unacceptable discomfort, i.e. tingling, tightness, redness, likely to discourage the user from applying this composition. The compositions according to the invention may be in the form of aqueous solutions, hydroalcoholic solutions, oil-in-water (O / W) or water-in-oil (W / O) or multiple (triple: W / O / W or O / W / O) emulsions or aqueous gels, a dispersion of oils in an aqueous phase, in particular using spherules, these spherules being able to be polymeric particles or better, lipid vesicles of ionic and / or non-ionic type, or even in the form of a powder, a serum, a paste or a flexible stick or even a stick. It may be of solid, pasty, or more or less fluid liquid consistency. These compositions are prepared according to the usual methods. Fat phase A composition may comprise at least one fatty phase. The fatty phase preferably contains at least one oil, in particular a cosmetic oil. It may also contain other fatty substances. The term "oil" means a non-aqueous compound, immiscible with water, liquid at room temperature (20°C) and atmospheric pressure (760 mm Hg). A fatty phase suitable for the preparation of the compositions, in particular cosmetic compositions, according to the invention may comprise hydrocarbon, silicone, fluorinated or non-fluorinated oils, or mixtures thereof. Preferably, a composition comprises less than 5.0% by weight of silicone oil(s), more preferably less than 2.0% by weight, even better less than 1% by weight, relative to the total weight of the composition, and even more preferably is free of silicone oil(s). A composition comprising a limited content of silicone oil(s) is advantageous- considerably more natural, but also lighter, less sticky and less rough to the touch, with a softer finish, than a composition comprising more than 5% by weight or more of silicone oil(s), relative to the total weight of the composition. Oils can be volatile or non-volatile. They can be of animal, vegetable, mineral or synthetic origin. By "non-volatile" is meant an oil whose vapor pressure at room temperature and atmospheric pressure is non-zero and less than 107 mm Hg (0.13 Pa). For the purposes of the present invention, the term “silicone oil” means an oil comprising at least one silicon atom, and in particular at least one Si-O group. The term “fluorinated oil” means an oil containing at least one fluorine atom. The term "hydrocarbon oil" means an oil containing mainly hydrogen and carbon atoms and possibly one or more heteroatoms such as oxygen or nitrogen atoms, and not containing any silicon or fluorine atoms. It may thus contain alcohol, ester, ether, carboxylic acid, amine and / or amide groups. Oils may optionally include oxygen, nitrogen, sulfur and / or phosphorus atoms, for example, in the form of hydroxyl or acid radicals. For the purposes of the invention, the term "volatile oil" means any oil capable of evaporating on contact with the skin in less than one hour, at room temperature and atmospheric pressure. Volatile oil is a volatile cosmetic compound, liquid at room temperature, having in particular a non-zero vapor pressure, at room temperature and atmospheric pressure, in particular having a vapor pressure ranging from 0.13 Pa to 40,000 Pa (10 to 300 mm Hg), in particular ranging from 1.3 Pa to 13,000 Pa (0.01 to 100 mm Hg), and more particularly ranging from 1.3 Pa to 1,300 Pa (0.01 to 10 mm Hg). Mention may in particular be made of volatile hydrocarbon oils having from 8 to 16 carbon atoms, branched C;-C,5 alkanes such as iso-alkanes (also called isoparaffins) in C;-C,5 isododecane, isodecane, isohexadecane and for example the oils sold under the trade names of Isopars or Permetyls, branched C;-C,5 esters such as isohexyl neopentanoate, and mixtures thereof. In particular, the volatile hydrocarbon oil is chosen from volatile hydrocarbon oils having from 8 to 16 carbon atoms and mixtures thereof. Mention may also be made of volatile linear alkanes comprising from 8 to 16 carbon atoms, in particular from 10 to 15 carbon atoms, and more particularly from 11 to 13 carbon atoms, for example such as n-dodecane (C2) and n-tetradecane (C,4) sold by Sasol respectively under the references Parafol® 12-97 and Parafol® 14-97, as well as their mixtures, the undecane-tridecane mixture, the mixtures of n-undecane (C1) and n-tridecane (C,;) obtained in examples 1 and 2 of application WO 2008 / 155059 from Cognis, and their mixtures. We can also mention the following mixtures of linear or branched alkanes, preferably of plant origin: - a mixture of branched C,5-Cy9 alkanes, for example that marketed by the company SEPPIC under the name EMOGREEN® LI5; - a mixture of linear and / or branched C;5-Cy9 alkanes, for example that marketed by the company SEPPIC under the name EMOGREEN® L19. A composition according to the invention may comprise at least one hydrocarbon oil chosen from volatile linear alkanes comprising from 11 to 13 carbon atoms, in particular an undecane-tridecane mixture, and linear and / or branched Cys-C;9 alkanes, in particular a mixture of linear and / or branched C;s - Cr alkanes. Examples of volatile silicone oils include linear volatile silicone oils such as hexamethyldisiloxane, octamethyltrisiloxane, decamethyltetrasiloxane, tetradecamethylhexasiloxane, hexadecamethylheptasiloxane and dodecamethylpentasiloxane. As cyclic silicone volatile oils, we can cite hexamethylcyclotrisiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, cyclohexasiloxane and dodecamethylcyclohexasiloxane, and in particular cyclohexasiloxane. Hydrocarbon, fluorinated and / or non-volatile silicone oils may also be mentioned. Examples of non-volatile hydrocarbon oils include: animal-derived hydrocarbon oils, such as squalane; hydrocarbon oils of mineral or synthetic origin such as: petroleum jelly, paraffin oils, polybutylenes, for example Indopol H-100 (molar mass or MW = 965 g / mol), Indopol H-300 (MW = 1340 g / mol), Indopol H-1500 (MW = 2160 g / mol) marketed or manufactured by the Amoco company, polyisobutenes and hydrogenated polyisobutenes, for example Parléam® marketed by the company Nippon Oil Fats, Panalane H-300 E marketed or manufactured by the Amoco company (MW = 1340 g / mol), Viseal 20000 marketed or manufactured by the company Synteal (MW = 6000 g / mol), the Rewopal PIB 1000 com- marketed or manufactured by Witco (MW = 1000 g / mol), polydecenes and hydrogenated polydecenes, for example Puresyn 10 (MW = 723 g / mol), Puresyn 150 (MW = 9200 g / mol) marketed or manufactured by Mobil Chemicals; the co- decene / butene polymers, polybutene / polyisobutene copolymers, for example Indopol L- 14: hydrocarbon oils of plant origin, such as plant squalane, synthetic ethers having 10 to 40 carbon atoms, such as dicaprylyl ether, - synthetic esters, such as oils of formula R,COOR,, in which R, represents a residue of a linear or branched fatty acid containing from 1 to 40 carbon atoms and R represents a hydrocarbon chain, in particular, branched containing from 1 to 40 carbon atoms provided that R, + Re is greater than or equal to 10. The esters may be, in particular, chosen from esters of alcohol and fatty acid, such as, for example, cetostearyl octanoate, esters of isopropyl alcohol, such as isopropyl myristate, isopropyl palmitate, ethyl palmitate, 2-ethylhexyl palmitate, isopropyl stearate, octyl stearate, hydroxylated esters, such as isostearyl lactate, hydroxystearate octyl, ricinoleates of alcohols or polyalcohols, hexyl laurate, esters of neopentanoic acid, such as isodecyl neopentanoate, isotridecyl neopentanoate, esters of isononanoic acid, such as isononyl isononanoate,isotridecyl isononanoate, octyl isononanoate, oleyl erucate, lauroyl isopropyl sarcosinate, diisopropyl sebacate, isocetyl stearate, isodecyl neopentanoate, isostearyl behenate; - polyol esters and pentaerythritol esters, such as dipentaerythritol tetrahydroxystearate / tetraisostearate, - fatty alcohols which are liquid at room temperature with a branched and / or unsaturated carbon chain having from 12 to 26 carbon atoms, such as 2-octyldodecanol, isostearyl alcohol, oleyl alcohol, - higher fatty acids C3-C7, such as oleic acid, linoleic acid, linolenic acid, and mixtures thereof, - carbonates, such as dicaprylyl carbonate, -non-phenylated silicone oils, such as caprylyl methicone, and -phenylated silicone oils, such as phenyl trimethicones, phenyl dimethicones, phenyl trimethylsiloxy diphenylsiloxanes, diphenyl dimethicones, diphenyl methyldiphenyl trisiloxanes, and 2-phenylethyl trimethylsiloxysilicates, dimethicones or phenyltri- methicone with a viscosity less than or equal to 100 cSt, trimethylpentaphenyl- trisiloxane, and mixtures thereof; as well as mixtures of these different oils. The oil(s) may be present in a composition according to the invention in a content ranging from 0.1% to 20% by weight, preferably from 3% to 15% by weight, relative to the total weight of the composition. The composition according to the invention may further comprise solid fatty substances such as, for example, fatty acids which are solid at room temperature, such as stearic acid, lauric acid, and palmitic acid; waxes, such as lanolin, beeswax, carnauba or candelilla wax, paraffin waxes, lignite waxes or microcrystalline waxes, ceresin or ozokerite, synthetic waxes such as polyethylene waxes, Fischer-Tropsch waxes, fatty alcohol waxes, butters such as vegetable butters; silicone resins such as trifluoromethyl-C;-C; -alkyldimethicone and trifluoropropyldimethicone; and silicone elastomers such as the products marketed under the names “KSG” by the company Shin-Etsu, under the names “Trefil” or “BY29” by the company Dow Corning or under the names “Gransil” by the company Grant Industries. Examples of fatty alcohol wax include lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, arachidyl alcohol, behenyl alcohol, lignoceryl alcohol, ceryl alcohol, montanyl alcohol, myricyl alcohol and mixtures thereof. Preferably, the fatty alcohol wax is cetyl alcohol. Examples of butter, particularly vegetable butter, include avocado butter, cocoa butter, shea butter, mango butter, coconut butter, apricot kernel butter, sal butter, and mixtures thereof, and in particular shea butter. These fatty substances can be chosen in various ways by those skilled in the art in order to prepare a composition having the desired properties, for example consistency or texture. The solid fatty body(ies) may be present in a composition according to the invention in a content ranging from 0.1% to 10% by weight, preferably from 0.5% to 5% by weight, relative to the total weight of the composition. Aqueous phase A composition may comprise at least one aqueous phase. The aqueous phase may comprise water and optionally a water-miscible organic solvent. The water used can be demineralized water and / or floral water such as rose water, cornflower water, chamomile water or linden water, and / or natural thermal or mineral water, such as Vittel water, Vichy basin water, Uriage water, Roche Posay water, La Bourboule water, Enghien-les-Bains water, Saint Gervais-les-Bains water, Néris-les-Bains water, Allevar-les-Bains water, Digne water, Maizières water, Neyrac-les-Bains water, Lons-le-Saunier water, Eaux Bonnes, Rochefort water, Saint Christau water, Fumades water and Tercis-les-bains, Avene water. The aqueous phase can also include reconstituted thermal water, that is, water containing trace elements such as zinc, copper, magnesium, etc., restoring the characteristics of thermal water. The water-miscible organic solvents that can be used in the composition of the invention may also be volatile. The composition may comprise water at a concentration ranging from 20% to 95% by weight, relative to the total weight of the composition. Preferably, the water is present in a composition according to the invention in a content ranging from 30% to 95% by weight, preferably from 40% to 90% by weight, and more preferably from 45% to 85% by weight, relative to the total weight of said composition. By "water-miscible organic solvent" according to the present invention is meant an organic compound which is liquid at room temperature and in particular has a miscibility in water of greater than 50% by weight at 25°C and atmospheric pressure. Among the water-miscible organic solvents which can be used in the composition according to the invention, mention may in particular be made of lower monoalcohols having from 1 to 5 carbon atoms, polyols, C; and C ketones, and C;-C aldehydes. Among the lower monohydric alcohols with 1 to 5 carbon atoms we can cite ethanol and isopropanol. By "polyol" suitable for the invention is meant a compound of alkyl type, linear, branched or cyclic, saturated or unsaturated, bearing on the alkyl chain at least two —OH functions, in particular at least three —OH functions, and more particularly at least four —OH functions. The polyols suitable for the formulation of a composition according to the present invention are in particular those having in particular from 2 to 32 carbon atoms, preferably from 3 to 16 carbon atoms. Polyols include pentaerythritol, trimethylolpropane, ethylene glycol, hexylene glycol, propylene glycol, 1,3-butylene glycol, isoprene glycol, pentylene glycol, caprylyl glycol, dipropylene glycol, glycerol, polyglycerols, such as glycerol oligomers such as diglycerol, polyethylenes glycols. When present, the water-miscible organic solvent(s) is (are) preferably present in a composition according to the invention in a content ranging from 1% to 20% by weight, better still from 3% to 15% by weight, preferably from 5% to 15% by weight, relative to the total weight of said composition. The aqueous phase may also include any water-soluble or water-dispersible compound compatible with an aqueous phase such as gelling agents, film-forming polymers, thickeners, surfactants and mixtures thereof. Depending on the viscosity of the composition to be obtained, one or more thickeners and / or gelling agents, in particular hydrophilic ones, i.e. soluble or dispersible in water, can be incorporated into the composition. Advantageously, the gelling agent is chosen from synthetic or natural or naturally occurring polymeric hydrophilic gelling agents, and mixtures thereof. For the purposes of the invention, the expression “of natural origin” is intended to designate polymeric gelling agents obtained by modification of natural polymeric gelling agents. The synthetic polymeric hydrophilic gelling agents may be chosen from crosslinked acrylic homo- or co-polymers, associative polymers, in particular polyurethane-type associative polymers, polyacrylamides and polymers and co-polymers of 2-acrylamido 2-methylpropane sulfonic acid, optionally crosslinked and / or neutralized, carboxyvinyl polymers, modified or not, and mixtures thereof, in particular as defined below. Among the crosslinked acrylic homo- or co-polymers, we can cite crosslinked sodium polyacrylates such as the products marketed under the names Octacare X100, X110 and RM100 by the company Avecia, those marketed under the names Flocare GB300 and Flosorb 500 by the company SNF, those marketed under the names Luquasorb 1003, Luquasorb 1010, Luquasorb 1280 and Luquasorb 1110 by the company BASF, those marketed under the names Water Lock G400 and G430 (INCI name: Acrylamide / Sodium acrylate copolymer) by the company Grain Processing. Among the carboxyvinyl polymers, we can cite for example modified or unmodified carboxyvinyl polymers, such as the products marketed under the names Carbopol® (CTFA name: carbomer). Among the polyacrylamides and polymers and copolymers of 2-acrylamido 2-methylpropane sulfonic acid which are optionally crosslinked and / or neutralized, mention may be made of poly(2-acrylamido 2-methylpropane sulfonic acid) marketed by the company Hoechst under the name Hostacerin® AMPS (CTFA name: Ammonium Poly-acryldimethyltauramide), crosslinked anionic copolymers of acrylamide and AMPS, in the form of a water-in-oil emulsion, such as those com- marketed under the name Sepigel® 305 (CTFA name: Polyacrylamide / C1314 Iso-paraffin / Laureth-7) and under the name Simulgel® 600 (CTFA name: Acrylamide / Sodium acryloyldimethyltaurate copolymer / Ishexadecane / Polysorbate 80) by the company Seppic, The natural or naturally derived polymeric hydrophilic gelling agents may be chosen from modified or unmodified celluloses, carrageenans, gellan gum, agar-agar, xanthan gum, alginate-based compounds, in particular sodium alginate, sceroglucan gum, guar gum, pullulan, cassia, karaya, konjac, tragacanth, tara, acacia or arabic gum, and mixtures thereof. Assets Advantageously, a composition may further comprise at least one additional cosmetic active ingredient. Examples of active ingredients include moisturizing agents, depigmenting agents, desquamating agents, humectants, anti-aging agents, healing agents, and mixtures thereof. Surfactants A composition according to the invention may comprise emulsifying surfactants, preferably non-ionic. The nonionic surfactants may be chosen in particular from poly(ethylene oxide) alkyl- and polyalkyl-esters, oxyalkylenated alcohols, poly(ethylene oxide) alkyl- and polyalkyl-ethers, polyoxyethylenated or non-polyoxyethylenated sorbitan alkyl- and polyalkyl-esters, polyoxyethylenated or non-polyoxyethylenated sorbitan alkyl- and polyalkyl-ethers, alkyl- and polyalkyl-glycosides or polyglycosides, in particular alkyl- and polyalkyl-glucosides or polyglucosides, sucrose alkyl- and polyalkyl-esters, polyoxyethylenated or non-polyoxyethylenated glycerol alkyl- and polyalkyl-ethers, polyoxyethylenated or non-polyoxyethylenated glycerol alkyl- and polyalkyl-ethers, geminal surfactants, cetyl alcohol, stearyl alcohol, and mixtures thereof. As oxyalkylenated alcohols, in particular oxyethylenated and / or oxypropylenated, those which may contain from 1 to 150 oxyethylene and / or oxypropylene units, in particular having from 20 to 100 oxyethylene units, in particular fatty alcohols, in particular C1-C1, and preferably C1-C1; these may be ethoxylated or not, for example, such as ethoxylated stearyl alcohol with 20 oxyethylene units (CTFA name “Steareth-20”) such as Brij® 78 marketed by the company UNIQEMA, ethoxylated cetearyl alcohol with 30 oxyethylene units (CTFA name “Ceteareth-30”) and the mixture of C1-C1 fatty alcohols containing 7 oxyethylene units (CTFA name “C15 Pareth-7”) such as that marketed under the name Neodol 25-7® mination by Shell Chemicals; or in particular oxyalkylenated (oxyethylenated and / or oxypropylenated) alcohols having from 1 to 15 oxyethylene and / or oxypropylene units, in particular ethoxylated C,-C,,, and preferably C,2-C1s fatty alcohols such as ethoxylated stearyl alcohol with 2 oxyethylene units (CTFA name “Steareth-2”) such as Brij® 72 marketed by the company Unigema. As alkyl- and polyalkyl-esters of sorbitan, polyoxyethylenated or not, those having a number of ethylene oxide (EO) units ranging from 0 to 100 are preferably used. Examples include sorbitan laurate 4 or 20 EO, in particular polysorbate 20 (or polyoxyethylene (20) sorbitan monolaurate), such as the product Tween © 20 marketed by the company Unigema, or polysorbate 60, sorbitan palmitate 20 EO, sorbitan isostearate, sorbitan stearate 20 EO, sorbitan oleate 20 EO or even Crémophor® (RH 40, RH 60, etc.) from BASF. Another example is the mixture of sorbitan stearate and sucrose cocoate, marketed under the name Arlacel® 212 1U-FL from Croda. As alkyl- and polyalkyl-glucosides or polyglucosides, those containing an alkyl group comprising from 6 to 30 carbon atoms and preferably from 6 to 18, or even from 8 to 16 carbon atoms, and containing a glucoside group preferably comprising from 1 to 5, in particular 1, 2 to 3 glucoside units are preferably used. The alkylpolyglucosides may be chosen, for example, from decylglucoside (Alkyl-C / C,1-polyglucoside (1.4)) such as the product sold under the name Mydol 10° by the company Kao Chemicals or the product sold under the name Plantacare 2000 UP® by the company Henkel and the product sold under the name Oramix NS 10° by the company Seppic; caprylyl / capryl glucoside such as the product marketed under the name Plantacare KE 37118 by the company Cognis or Oramix CG 110® by the company Seppic;laurylglucoside such as the product marketed under the name Plantacare 1200 UP® by Henkel or Plantaren 1200 N® by Henkel; cocoglucoside such as the product marketed under the name Plantacare 818 UP® by Henkel; caprylylglucoside such as the product marketed under the name Plantacare 810 UP® by Cognis; the mixture of arachidyl glucosyl and behenyl alcohol and arachidic alcohol, whose INCI name is Arachidyl Alcohol (and) Behenyl Alcohol (and) Arachidyl Glucoside, marketed under the name Montanovê 202 by Seppic; the mixture of cetearyl alcohol and cetearyl glucosyl, whose INCI name is Cetearyl alcohol / cetearyl glucoside marketed under the name Montanov® 68 by Seppic and their mixtures. A composition according to the invention or as implemented for the use according to the invention may comprise between 0.1% and 30% by weight of emulsifying surfactant, preferably between 0.2% and 20% by weight, more preferably between 0.5% and 10% by weight, relative to the total weight of the composition. The expressions “between … and …”, “includes from … to …”, “formed from … to …”, and “ranging from … to …” must be understood inclusively, unless otherwise specified. The invention is illustrated in more detail by the examples presented below. Unless otherwise indicated, the quantities indicated are expressed as a percentage by mass. Examples Example 1: principle if. eti: Î' to the invention The active ingredient of Example 1 is obtained from an Aureobasidium pullulans yeast isolated from rose bushes. The active ingredient of Example 1 is obtained by the following process: a. Cultivation of Aureobasidium pullulans in a suitable culture medium b. Solubilization of the biomass of the yeast Aureobasidium pullulans in water, at a rate of 50g / l, c. Extraction of sugars, d. Heat treatment, e. Separation of soluble and insoluble phases, f. Purification by molecular sorting, g. Concentration, and h. Sterilizing filtration. The active ingredient obtained has the following characteristics: - Dry Matter Content = 20.1 g / L including: - Total Sugar Content (according to the Dubois method) = 6.9 g / L (34%, by weight relative to dry matter) 1. Alpha-linked glucose oligosaccharide content = 2.5g / L ii. Beta-linked glucose oligosaccharide content = 2.5g / L - Peptide content (according to the KJELDHAL method) = 6.6 g / L (33%, by weight relative to dry matter) - Mineral ash content = 2.5 g / L (12%, by weight relative to dry matter) -pH=3.5 - Clear, very light yellow liquid, faint odor Example 2: Active ingredient outside the invention The active ingredient of Example 2 is also obtained from an Aureobasidium pullulans yeast isolated from rose bushes. The active ingredient of Example 2 is obtained by the following process: a. Culture of Aureobasidium pullulans in a suitable culture medium b. Solubilization of the biomass of the yeast Aureobasidium pullulans in water, at a rate of 50g / l, c. Protein extraction, d. Heat treatment, e. Separation of soluble and insoluble phases, f. Purification by molecular sorting, g. Concentration, and h. Sterilizing filtration. The active ingredient obtained has the following characteristics: - Dry Matter Content = 26.8 g / L including: - Total Sugar Content (according to the Dubois method) = 2.5 g / L (9%, by weight relative to dry matter) - Peptide content (according to the KJELDHAL method) = 12.4 g / L (46%, by weight relative to dry matter) - Mineral ash content = 5 g / L (19%, by weight relative to dry matter) -pH=3.6 - Clear, very light yellow liquid, faint odor. Example 3: Active ingredient outside the invention The active ingredient of Example 3 is obtained from the culture supernatant of the biomass of Aureobasidium pullulans. a. Culture of Aureobasidium pullulans in a suitable culture medium b. Physical separation to recover the culture supernatant from the biomass c. Sterilizing filtration The active ingredient obtained has the following characteristics: - Dry Matter Content = 9.6 g / L including: - Total Sugar Content (according to the Dubois method) = 1.6 g / L (17%, by weight relative to dry matter) - Protein content (according to the Lowry method) = 0.11 g / L (1%, by weight relative to dry matter) - Mineral ash content = 6.2 g / L (65%, by weight relative to dry matter) -pH=6.9 - Clear, light yellow liquid, faint odor. Example 4: Effect of the active ingredient in accordance with the invention on the aging of cells in the epidermal compartment The present study aims to study the expression of certain genes and to determine the level of certain proteins in keratinocytes treated with the different extracts. The keratinocytes are aged by means of UVB radical stress, or are derived from elderly donors. Table 1 lists the epidermal compartment genes modulated during aging by radical stress. [Tables 1] Symbol Name } ï | HSP9OAAI | heat shock protein 90 alpha family class To memes | SIRTI sirtuin Ê Table 2 lists the epidermal compartment proteins modulated during aging by radical stress. [Tables 2] Name Symbol Parkinson disease protein 7 DI-1 { ï ï 5 Tumor necrosis factor receptor superfamily member 6 | TNRe { The results of the study are presented in Tables 3 to 5 below. Table 3 represents the expression of the HSP90AA 1 and SIRT1 genes in keratinocytes subjected to UVB radical stress and treated with the different extracts. [Tables 3] | HSPS0AA1 (#0) | Efficiency (76) SIRT! (?6) Efficiency ci come te CO Kecatisocsres old parent A 0 — E Witness 39 16 EXAMPLE 1 0.5% | 58 +48 $5 +106 EXAMPLE 2 0.5% | 46 +18 20 +25 EXAMPLE 3 0.5% 44 +13 3 2 EXAMPLE 3 0.5% | 44 +13 3 2 The active ingredient according to the invention, rich in sugars, (example 1) has a better effect on the expression of the HSP90AA 1 and SIRTI genes in keratinocytes aged by UVB stress than the extracts outside the invention (example 2 and example 3). Table 4 below represents the expression levels of DJ-1 and TNR6 proteins in keratinocytes aged by UVB stress and treated with the different extracts. [Tables 4] p-14 + |-8 4817 |-18 [Tables 4] | D3-1 (%) Efficiency |TnRs ©) Di-1 © 8%, [Re 11 ee L NC Le St En Witness 2496 507 EXAMPLE 1 0.5%] 2227 | -11 310 | -39 EXAMPLE 2 0.5%| 2290 | -8 417 | -18 — EXAMPLE 3 0.5%| 2453 |-2 507 ü EXAMPLE 3 0.5% 2353 | -2 507 G The active ingredient according to the invention, rich in sugars, (example 1) has a better effect on the level of DJ-1 and TNR6 proteins in keratinocytes aged by UVB stress than the extracts outside the invention (example 2 and example 3). Table 5 below represents the expression levels of the DJ-1 protein in keratinocytes from elderly donors and treated with the active ingredient in accordance with the invention (example 1). [Tables 5] DM-14%) | | Efficiency (56) re ceases eos to NES M 17 / 7107 EXAMPLE 10.5% |54 [54 The active ingredient (example 1) according to the invention, rich in sugars, has a significant effect on the expression rate of the DJ-1 protein in keratinocytes from aged donors. This result confirms the results obtained on keratinocytes aged by radical stress. Thus, the sugar-rich extract according to the example | shows an effect on the pathways of aging metabolism (HSP90AA1 +48%, SIRT1 +106%, DJ 1 -54%, TNR6 - 39%). The protein-rich extract from Example 2 has a much weaker effect on the aging pathways of metabolism. Therefore, it is less effective than the extract from Example 1. The extract according to Example 3, extracted from the supernatant, does not show any effect on the pathways of aging metabolism in the epidermal compartment. Also, an extract rich in sugars allows to obtain an improved effect on the pathways of aging metabolism. Example 5: Effect of the active ingredient in accordance with the invention on the migration of aged keratinocytes The present study aims to investigate the ability of different extracts to increase cell migration of normal human keratinocytes. Cell migration is the ability of certain cells to move, this migratory capacity is reduced with age. The present study was carried out on keratinocytes from elderly donors (> 60 years). Table 6 below represents the quantification of keratinocyte migration into the wound carried out in cultures of elderly keratinocytes, treated with the different extracts. [Tables 6] + You Migration / | Efficiency / Control (8) | Control (6) | Control 100 EXAMPLE 3 0.5% | 100 i — The extract according to Example 3 does not have any effect on the migration of aged keratinocytes. Conversely, the extract according to Example 1 stimulates the migration of aged keratinocytes by 23%. Here again, the sugar-rich extract according to the invention of Example 1 allows an improved effect in stimulating the migration of aged keratinocytes and therefore anti-aging efficacy. Example 6: In vitro effect of the principle conf to the i i ] of the barrit function to A. Materials and methods Culture and treatment of reconstructed skins The Aureobasidium pullulans extract is that prepared in Example 1 above. Human keratinocytes were seeded onto inserts and then incubated at 37°C in an atmosphere containing 5% CO. Between the second and ninth On the incubation day, the culture medium is changed every two days. Reconstructed epidermis are then treated systemically with either 0.25% and 0.50% (V / V) Aureobasidium pullulans extract or 250 μm niacinamide, then incubated at 37°C under an atmosphere containing 5% CO, from day 9 to day 17. On day 17, the reconstructed skins are then recovered and treated in different ways depending on the analytical test performed, namely: - for immunohistofluorescence analysis, the reconstructed skins are recovered, fixed, dehydrated and embedded in paraffin. 4 µm sections are then made using a microtome (Leica). - for a QPCR test, the reconstructed skins are recovered and the RNAs were extracted in full. Analysis of the synthesis of filaggrin, loricin and claudin-! by immunohistofluorescence For this test, the primary antibodies used are as follows: - Mouse monoclonal anti-filaggrin antibody - Rabbit polyclonal anti-loricrin antibody - Mouse monoclonal antibody anti-claudin-1 The secondary antibodies used are as follows: - Alexa Fluor® 488-coupled anti-rabbit IgG antibody - Alexa Fluor® 488-coupled anti-mouse IgG antibody Visualization was performed using an IX 70 microscope (Olympus) coupled with an image analysis system (NIS-Elements software, Nikon). The rate of the different synthesized markers is proportional to the green fluorescence intensity present on the reconstructed epidermis. Quantification was performed using an image analysis script in python language. The results are expressed in arbitrary units (AU). lysis of the ion of Z0-1, CK10, involucrin TGMI PCR SR For this analysis, the RNAs were reverse-transcribed and the complementary DNAs obtained were analyzed by the quantitative PCR technique. The mRNAs of the proteins RPS18, GAPDH and GUSB, internal reference controls, were analyzed in parallel with the mRNAs of ZO-1, CK10, involucrin and TGMI1. Fluorescence incorporation quantification (SYBR Green) was continuously measured using a LightCycler LC480 thermal cycler (Roche) and Ct analysis (relative quantification) was performed using LC480 software (Roche). B. Results *: significant results according to Student's t test / RECONSTRUCTED EPIDERMIS control (p < 0.05) %%; significant result according to the Student test / RECONSTRUCTED EPIDERMIS control (p < 0.01) *#X; significant results according to Student's t-test / RECONSTRUCTED EPIDERMIS control (p < 0.005) Immunohistofluorescence studies on the effect of Aureobasidium pullulans extract on the synthesis of epidermal markers: filaggrin, loricrin and claudin-1 [Tables 7] {07 1st UT | - Synthesis Synthesis Synthesis _ LL Effectiveness' | of ; of Effectiveness; | of ; ; Effectiveness' ; ; 2. witness claudine- ; Ftangriee witness (Ha) ls en : ae witness (6) Gi LA) 10 A) UA) 664 | - 250 | - 241 | - _ | +84 | 286* | + | 2924 | 21 — | +817 | no” [+4 | 2351* | +39 4* | 42 | 214 |- | 266 |=10 * the Aureobasidium pullulans extract of the example | is tested in the form of a mixture comprising 2.15% by weight of dry matter of Aureobasidium pullulans extract, 15% by weight of propylene glycol, qs. water. The study of the effect of Aureobasidium pullulans extract on the synthesis of epidermal markers filaggrin, loricrin and claudin-1 showed significant results compared to the control. For example, the effect of Aureobasidium pullulans extract on the synthesis of claudin-1 is significant compared to the control. QPCR studies [Tables 8] [= | 08 | | |- | 72 |- Phrase | Efficiency” | Esgrenion | Efficiency | Expression | Eitcarte | FPreseion Erac | of 20-1 | witness | of CKIO| witness | of TOM | witness ue tés bp cu es Lo 2% es aa Ténois qe TE 5 TT T0 TT 1: Extat d'évreobacidun folded ju | | u# | es | Peu | = | ire | æ the eseagle 1 to its Nacinmide 20 In |- |- E: |- um * the Aureobasidium pullulans extract of the example | is tested in the form of a mixture comprising 2.15% by weight of dry matter of Aureobasidium pullulans extract, 15% by weight of propylene glycol, qs. water. The study of the effect of Aureobasidium pullulans extract on the synthesis of epidermal markers ZO-1, CK10, TGM], and involucrin showed significant results compared to the control. For example, the effect of Aureobasidium pullulans extract on the expression of CK10, or involucrin is significant compared to the control. As a result, Aureobasidium pullulans extract helps improve the skin's barrier function. E le 7: In vivo effect of the princi if conf: l i ii the skin barrier function A. Materials and methods The Aureobasidium pullulans extract is that prepared in Example 1 above. The composition according to the invention, according to Table 9 below, called “tested composition” below, as well as a second placebo formula identical to the “tested composition” without the Aureobasidium pullulans extract, were applied to the half-face according to a predefined randomization for 42 days, by light massages until the composition was absorbed. The values ​​are expressed as a percentage by weight of active ingredient, relative to the total weight of the composition. [Tables 9] alcohol / cetearyl C\12-14 Ingredients Amount in percentage Isononyf isononanoate (Massocare ININ, | 5.20% CQ MASSO) Beheny! alcohol / arachidyl glucoside / | 3.0% arachidyt alcohot {Montanov 202, Seppi 2.5% Cetearyi alcohol / cetearyi glucoside | 2.0% Montanor 68, Seppic} Preservatives 1.0% Polyacrylamide / C13-14 isoparafin / | 0.3% laureth 7 (Sepisef 305, Seppic Citric acid sppHS Water 2e 100% * the Aureobasidium pullulans extract of the example | is tested in the form of a mixture comprising 2.15% by weight of dry matter of Aureobasidium pullulans extract, 15% by weight of propylene glycol, gs. water. The user panel (20 volunteers) completed a 14-day wash-out period, applying the placebo formula twice daily. Then, the users applied a composition containing Aureobasidium pullulans extract and the placebo formula to half-face every morning and evening on skin free of cream and / or makeup for 42 days. On the day of the measurements, the volunteers came to the laboratory without having applied any product to the areas of interest in the morning (no cream or makeup). Study of the barrier function Transepidermal water loss (TEWL) measurements were performed using a Tewamètre® TM 300 (Courage&Khazaka), comprising a probe that measures the water vapor gradient established between the skin surface and the ambient air, which provides information on the quality of the barrier function of the stratum corneum. The PIE measurements were performed on symmetrical areas of the cheeks at different times during the study. A decrease in TEWL is characteristic of an improvement in the skin barrier function. The effect of Aureobasidium pullulans extract on TEWL was measured on the face compared to placebo after 14, 28 and 42 days of twice-daily application on the half-face. Study of skin microrelief The study of skin microrelief was based on prints analyzed by fringe projection. These silicone polymer impressions were taken on the cheeks at different times during the study. Volume acquisitions of these prints were then carried out using a fringe projection device dedicated to the 3D measurement of the relief of the prints (Eotech). This system (DermaTOP 1303) includes a measuring sensor combining a projector and a high-resolution CCD camera connected to Optocat acquisition software (Eotech). The studied area is automatically cut out from the original acquisition. The parameter retained for this study is the Sa parameter (mm) which corresponds to the arithmetic mean of surface roughness. The higher this parameter, the rougher the surface. A decrease in this parameter is characteristic of an improvement in the microrelief. A. Data processing The effect of Aureobasidium Pullulans extract and placebo was evaluated by studying the rate of change between JO and the different times of interest (Dx), reflecting the variation between before and after treatment. [Formula 1] {VM ue VM 30) AfJO (M}=— VM 19 with- VMus Average value over the treated areas having treatment. VMr Average value on the affected area after x days of daily application. The effect of the Aureobasidium Pullulans extract compared to the placebo formula is evaluated by taking the difference between the rate of change of the formula containing the Aureobasidium Pullulans extract and that of the placebo formula: tones Eee TESTS pong ao. . (Formula 2] With : (A / JO)produce: rate of evolution compared to JO on the area treated by the com- tested position including Aureobasidium Pullulans extract after x days of daily applications. (A / JO)pracero: rate of evolution compared to JO on the area treated by the placebo after x days of daily applications. Statistical analysis of data Comparisons of the results obtained between JO and the different times of interest, after using each of the formulas and between the effect of the formula containing the Aureobasidium Pullulans extract and that of the placebo formula were carried out according to the Student t-test on paired data, except when the result of the Shapiro-Wilk Normality test is less than 5%. In this case, the statistical analysis was carried out using the non-parametric Wilcoxon Signed Rank test. In both cases, the test is used unilaterally with a risk threshold set at 5%. StatgraphicsTM Centurion version XVI software was used to carry out these analyses. A. Results Barrier function study: Effect of Aureobasidium Pullulans extract on TEWL (g / h / m°) measured on the face compared to placebo after 14, 28 and 42 days of twice-daily application [Tables 10] |-- 1756 | +43 | +31 |- Tested composition including | | Placebo Aureabasidiun extract | Pnihdans Votontaires | JŸ 1 742 SEM 0.52 1045 10.38 (038 [052 10358 1042 [050 ane, |- +56 |+43 | +1 |- -5.0* | -11.1* |-224* | p-value |- *: significant results / JO according to Student's t test (p<0.05) Compared with placebo, the formula containing Aureobasidium pullulans extract in emulsion shows an improvement in the quality of the barrier function from 14 days of treatment (-14.6%, p = 0.0026). This effect continues after 28 and 42 days of treatment with respectively -15.4% (p = 0.0066) and -15.5% (p = 0.0004) and was observed in more than 75% of volunteers at the different measurement times). Skin microrelief study: Smoothing effect of Aureobasidium pullulans extract on the microrelief of the cheeks, parameter Sa (mm) compared with placebo after 14, 28 and 42 days of twice-daily application. [Tables 11] |- |-0.5 | +5.2 1 +123 |- Tested composition including | | Placebo extract of Anreobasidiums | Pullulans Volunteers 10,742 Fr SEM 0.003 | 0.002 [0063 | 0.003 9.003 0.003 | 0.003 ane, |- |-45 +13 |- -9.0** 39 | p-value 03788 | 0.9732 | 0.6491 | - 0.0069 | 0.8191 | 0.1952 | p-vator Compared with placebo, the formula containing Aureobasidium pullulans extract in emulsion showed a significant improvement in skin microclic after 14 days of treatment by decreasing the Sa parameter by 8.1% (p = 0.0120; effect observed in 65% of volunteers). Example 8: In vitro effect of the active ingredient in accordance with the invention alone and in as- A. Materials and methods The extract of Aureobasidium pullulans is that prepared in Example 1 above. The effects of the extract of Aureobasidium pullulans and C- beta-D-xylopyranoside-2-hydroxy-propane (C-Xyloside, Pro-xylane'M) and their combination were evaluated on normal human epidermal keratinocytes (NHEK) by assessing the expression of the markers by in situ immunofluorescence labeling and image analysis: - expression of differentiation markers: Transglutaminase K (TGK), filaggrin and involucrin, - expression of tight junction proteins: claudin 1, zonula occludens-1 (ZO-1) and occludin, The compounds were tested at a non-cytotoxic concentration. - Normal human keratinocytes: NHEK, Bioalternatives reference K341 used in the 3rd passage - Culture conditions: 37°C, 5% CO, - Culture medium: Keratinocyte SFM (serum free medium) supplemented with Epidermal Growth Factor Pituitary extract - Test medium: Keratinocyte SFM (serum free medium) Compounds tested [Tables 12] Aureohasiditon Extract | - Liquid pullulans* - Store at room temperature. Protected from heat and humidity. conservation 1% in the middle of | 0.03%, Ë | cooking 0.1% and 0.3% - Liquid IDE- |- conserve temperature (C- | ambient PRO- Cu C-beta-D- XYLOPYRANOSIDE- 2-BYDROXKY- PROPANE C XYLOSIDE, PRO XYLANEM _ * the Aureobasidium pullulans extract of the example | is tested in the form of a mixture comprising 2.15% by weight of dry matter of Aureobasidium pullulans extract, 15% by weight of propylene glycol, qs. water. “1e C-beta-D-XYLOPYRANOSIDE-2-HYDROXY-PROPANE is tested as a mixture comprising 35% by weight of active ingredient of C-beta-D-XYLOPYRANOSIDE-2-HYDROXY-PROPANE, 25% by weight of propylene glycol, gs. water. - Positive control for the expression of markers: TGK, filaggrin, involucrin, claudin 1, ZO-1 and occludin: CaCl, Sigma, ref. C7902, stored in 150 mM ultrapure water solution, tested concentration = 1.5 mM - Positive control for marker expression: Collagen IV: TGF-B R&D Systems, ref. 240-B, stored in 20 ug / ml solution of 4 mM HCl / 0.1% BSA, tested concentration from 1.6 to 10 ng / ml. Cultures and treatments TGK, claudin 1, ZO-1, collagen IV: Keratinocytes were seeded into 96-well plates and cultured in culture medium for 24 hours. The medium was then replaced with test medium containing or not (control) the test compounds, the combination, or the reference compound, and the cells were incubated for 72 hours. Filaggrin: Keratinocytes were seeded in a 96-well plate and cultured in culture medium for 192 hours with renewal of the culture medium after 24 and 96 hours. The medium was then replaced with a test medium containing or not (control) the tested compounds, the combination or the reference compound and the cells were incubated for 72 hours. Involucrin and occludin: Keratinocytes were seeded into 96-well plates and cultured in culture medium for 24 hours. The medium was then replaced with test medium containing or not (control) the test compounds, the combination, or the reference compound, and the cells were incubated for 144 hours with a renewal of the treatment after 72 hours. In situ immunofluorescent labeling and image analysis Fixed cells Cells were rinsed with PBS solution, fixed, and permeabilized. Cells were then labeled with a specific primary antibody (Table 13). The primary antibody was then revealed with an appropriate fluorescent secondary antibody (Table 13), and cell nuclei were stained in parallel with Hoechst 33258 solution (bisbenzimide, Sigma, ref. B1155). [Tables 13] Protein Primary antibody Secondary antibody TGK Anti-TGK (Anti-TGK} GAR-Alexa 488 Proteintech, ref. 12912-3-AP Invitrogen, re£ A11008 Filaggrin Anti-filaggrin GAM-Alexa 488 Santa Cruz, ref. SC-66192 Invitrogen, re£ A11001 Involucrine Anti-involucrin GAM-Alexa 388 Siema, ref. [9018 Invitrogen, ref A11001 Claudine! Invitrogen, ref. A11001 Occludin Anti-occluein GAM-Alexa 455 Invitrogen, ref. 33-1500 Invitrogen, ref. A11001 Collagen IV | Anti-collagen IV GAM-Afexa 455 Chemicon, ref. MAB6308 Invitrogen, ref A11001 Microscopic observation and image analysis Image acquisition (5 photos / well) was performed with an INCell AnalyzerTM 2200 (GE Healthcare, x20 objective). Labeling was quantified by measuring fluorescence intensity and normalizing fluorescence intensity to total cell number (Digital Data Integration with Developer Toolbox 1.5 software, GE Healthcare). Data processing Raw data were analyzed using Microsoft Excel software. Intergroup comparisons were performed by unpaired Student's t-test. Statistical analysis can be interpreted if n>5, however for n <s5 les valeurs sta- tistiques sont à titre indicatif. The formulas used are: The standard error of the mean is calculated using the following formula: [formula 3] sem = Sd / vn The standard error of the mean (sem) is a measure of how far the sample is likely to deviate from the true population mean. The sem is calculated as the sd (standard deviation) divided by the square root of the sample size. The viability percentage is calculated using the following formula: [formula 4] Viability (%) = (DOschnrinon / DO control) X 100 OD: optical density. B. Results ns: 0.05, not significant #: 0.01 to 0.05, significant #**: 0.001 to 0.01, very significant #*%: < 0.001, extremely significant The results by marker are reported in the following tables 14 to 21 [Tables 14] Occludin expression Integration significance Compound Concentration | fluo sd control Control - 100 11 - CaCL 1.5mM 296 27 *+ Joss | _js2 juT ee Ua | 0e | Compound Concentrate Control - CaCL 1.5 mM Aureobasidium uilrlars extract 0.39% C-beta-D-xylopyranoside-2- hydroxy-propane (C- Xytoside, Pro- xylane5"N 0.3% Auveobasidiue puiluians extract + C-beta- D-xylopyranoside-2- hydroxy-propane (C- Xyloside, Pro-|0.,3% xylane"X +03% [Tables 15] Expression of ZO-1 I 1310 9 |+ Compound Integration significance Concentration | fluo sd control Control - 190 Z - Cach 15mM 119 4 & Extract 0.03% 96 1 as of Aureobasidium 01% 23 14 ns nefielans 0.3% 100 3 as C-beta-D- 0.03% 111 3 as xylopyranoside-2- [0.1% 124 11 ns fydroxy-propane {C- Xyloside, Pro- vlaneTM 0.3% 127 12 as Extract 0.03% of Aureobasidium + 0.03% 137 $ = pullulans + C-beta-| 0.1% D-xylopyranoside-2- | + 0.1% 122 7 + hydroxy-propane (C- Xyloside, Pro-| 0.3% plane +0.3% 130 9 = [Tables 16] Claudine's expression! ie I ane Pro-|0.1% +G1% Integration significance Compound Concentration | fluo se control Control - 100 13 - CaCt: 1.5mM 200 16 "x Extract 0.03%5 si 20 as of Aureobasidium elluians 0.1% 89 3 us €-beta-D- 0.03% 184 13 = xylopyranoside-2- hydroxy-propane {C-Xyloside, Pro- ylan TMS 0.1% 204 30 * Extract 9.03% of Aureobasidium + G.0384 172 16 * pullulans + C-beta-D-xylopyrancside- 2-hydroxy-propane (C-Xyloside, | Pro-10.1% xylanTX +G.1% 221 14 ue xylan?) | _|+01% | _|æ21 14 + [Tables17] Expression of Invoiucrin Integration significance Concentration | fluo sd control - 100 $ - 1.5 mM 126 4 * 0.1% __132 5 * 23% 148 3 + 0.1% 109 4 ns —ito je. ms _usz_ Ye + RE SR AE TRI SES Compound Concentration | fluo sd cont Control - 100 $ - CaCk 15 mM 126 4 * Extract 0.1% __|132 5 * of Aureobasidium pelielens 2.3% 148 3 = C-beta-D- 0.1% 109 4 25 xylopyranoside-2-hydroxy-propane (C-Xyloside, | Pro- xylaneTM 0.3% 110 é ns Extract 3.1% of Aureobasidium +0.1% 132 6 + Pullulans + C-beta- D-xylopyranoside- 2-hydroxy-propane (C-Xyloside, Pro-|0.3% xvianeT* +093% 162 12 * [Tables 18] Expression of laggrin _—, _ Integration significance Compound Concentration | fluo sd control Control - 100 #1 - CaCk 15mM 159 14 < Extract 0.1% 157 13 = AE soda EN me SDS aan 0.3% 179 28 0.1% 114 ii _jia7 I am Compound Concentration | fluo sd contré Contrôfe - 100 11 - CaCk 15mM 159 14 $ Extract 0.1% 157 13 * of Aureobasidin stools 2.35% 179 24 * C-beta-D- 0.1% 114 ii ns xylopyranoside-2- hydroxy-propane (C-Xyloside, Pro- glaneTM 0.3% 127 18 ns Extract 0.1% of Aureobasidiisun +0.19 157 47 $ pullulans + C-beta- D-xylopyranoside- 2-hydroxy-propane (C-Xyloside, Pro- |0.3% xviane" +03% 198 7 ax [Tables 19] TGK Expression Integration Significance Compound Concentration | fluc sd control Control - 100 8 - CaCk 15mM 503 163 ** Extract 0.03% 84 $ ns of Aureobasicliun 0.1% 93 ê ns tlrelams 0.3% 113 459 ns CB-beta-D- 0.05% 124 22 ns Xylopyranoside-2- [019% 158 7 sx Jess _Jas _|E Compound Concentration | fluo sd countered Control - 100 8 - CaCk 15mM 503 163 £x Extract 0.03% 84 $ ns of Aureobasiclinn 0.1% 93 ê ns slicloms 0.3% 113 49 ms CB-beta-D- 0.05% 124 2 ns xylopyranoside-2- [019% 158 7 sx hydroxy-propage {C-Xvloside, Pre- xylaneTM 0.3% 235 45 * Extract 0.03% of Aureobasidinn +0.03% 246 28 a Pullulans + C-beta-| 0.1% D-xylopyranoside- [+019 225 32 » 2-hydroxy-propane (C-Xvloside, Pro- [0.3% rlaneT* +039 388 42 a [Tables20] significance ve control + jee Integration Concentration | fluo sd - $100 10 na / ml 176 9 0.35% 114 _Ji20 _j12 _jms | ne Pro- 03% ane Pro-|0.3% +0.3% Under control conditions, basal expression of differentiation markers and tight junction proteins, TGK, filaggrin, involucrin, claudin 1, ZO-1, and occludin, in NHEKs was either very low or limited to a small number of cells. Treatment of NHEKs with the positive control CaCL, tested at 1.5 mM, significantly stimulated the expression of TGK (903% of control), filaggrin (159% of control), involucrin (126% of control), claudin-1 (200% of control), ZO-1 (119% of control), and occludin (296% of control). These results were expected and validated the assay. At the dermoepidermal junction, basal collagen IV expression was very low. Treatment of NHEKs with the tested TGF-B at 10 ng / ml significantly stimulated collagen IV expression (176% of control). These results were expected and validated the assay. Under the experimental conditions of this test, Aureobasidium pullulans extract induced a significant increase in the expression of filaggrin, involucrin, and occludin. The combination of Aureobasidium pullulans extract and C- beta-D-xylopyranoside-2-hydroxy-propane (C-Xyloside, Pro-xylane"M) also has stimulated the expression of the markers considered. The main effects, slightly stronger than those of Aureobasidium extract alone, were: - a significant increase in the expression of collagen IV at the highest concentration of the combination while only no efficacy was observed, - an increase in TGK in a synergistic manner, and - a significant increase in ZO-1 expression with a similar effect at the 3 concentrations tested while only no efficacy was observed. As a result, the extract of Aureobasidium pullulans, optionally in association with C-beta-D-xylopyranoside-2-hydroxy-propane, helps to combat the signs of skin aging and improve the skin's barrier function. Example 9: Cosmetic composition On a préparé la lotion ci-dessous : [Tableaux21] TETRASODIUM GLUTAMATE DIACETATE B1IS-PEG-IS METHYL ETHER DIMETHYL SILANE Eau Florale de Rose GLYCERINE PROPANEDIOL HYDROXYPROPYL mi @ 6 Concentration Lecce eme pr mr ED nn TETRASODIUM GLUTAMATE DIACETATE loi TT cu me EE me RE TT mm a roman mimameomamet DDPANYWI AWXZA ï (PROXYLANE) a CRÉGBASIDREM FULLULANS beau sr 000000 F'acrpreectas 4 $ Î fexemple 1* ACTE f= ACIDE XYLITYLGLUCOSIDE (and) ANHYDROXYLITOL (and) 45 OT VITAE 1835 XYLITOL 10,5 PEG-40} FAT —Rzz—x—#z="mammmmmmnmnnn +2 coton * the Aureobasidium pullulans extract of the example | is incorporated into the composition in the form of a mixture comprising 2.15% by weight of dry matter of Aureobasidium pullulans extract, 15% by weight of propylene glycol, qs. water. The lotion was applied to the skin of the face.

Claims

Claims

1. Use of a cosmetic active ingredient comprising at least one extract from the yeast biomass of the species Aureobasidium pullulans, characterized in that the extract comprises at least 25% sugars, in dry matter weight of the extract, or in a composition the including, as a cosmetic active ingredient.

2. Use according to claim 1, characterized in that it is intended to prevent and / or treat the signs of skin aging and / or to strengthen and / or improve the skin barrier function.

3. Use according to claim 1 or 2, characterized in that it is intended for skin hydration and / or for improving the quality of the skin surface, in particular to the improvement of the radiance of the skin and / or improving the evenness of the complexion and / or the di- reduction of skin microreliefs.

4. Use according to any one of the preceding claims, ca- characterized in that the yeast is isolated from rose bushes, more preferably- primarily from the flowers, and / or thorns and / or roots of Rosa sp.

5. Use according to any one of the preceding claims, ca- characterized in that the extract comprises at least 45% sugars, in dry matter weight of the extract, and in particular the sugars of the extract are composed of at least 80% oligosaccharides, by weight of dry matter of sugars, said oligosaccharides preferably being alpha-linked glucose oligosaccharides and / or oligosaccharides of beta-linked glucose and said oligosaccharides having for example a molar mass less than 1800 Da.

6. Use according to any one of the preceding claims, ca- characterized in that said cosmetic active ingredient is presented in liquid form or solid form.

7. Use according to any one of the preceding claims, ca- characterized in that said cosmetic active ingredient is capable of being obtained by a process comprising the following steps: a. cultivation of Aureobasidium pullulans biomass in a medium of culture, b. solubilization of at least 50g / L of Aureobasidium pullulans in water, c. extraction, preferably extraction of sugars, d. heat treatment, €. separation of the soluble and insoluble phase, and recovery of the phase soluble, f. purification by molecular sorting, and possibly decolorization and deodorization, and g. possibly concentration and sterilizing filtration.

8. Use according to any one of the preceding claims, ca- characterized in that said cosmetic active ingredient is in association with at least one C-glycoside.

9. Use according to the preceding claim, wherein said C- glycoside is of the following general formula (I): go ® in which: - R represents: - a linear alkyl radical, saturated in C1 to C20, preferably in Cl to C1O, or unsaturated in C2 to C20, preferably in C3 to C10, or a radical branched or cyclic, saturated or unsaturated, C3 to C20 alkyl, of preference in C4 to C10; - a linear saturated hydrofluoro- or perfluoro-alkyl radical in C1 to C20, preferably C2 to C10, or unsaturated C2 to C20, preferably C2 to C10, or branched or cyclic, saturated or unsaturated, C3 to C20, of preference in C4 to C10; - a phenyl or benzyl radical, - the hydrocarbon chain constituting said radicals may, where appropriate where appropriate, be interrupted by 1, 2, 3 or more chosen heteroatoms among: an oxygen, a sulfur, a nitrogen, a silicon, an atom halogen, - and which may optionally be substituted by at least one radical chosen from: -OR4, -SR4, -NR4R5, -COOR4, -CONHR4, -CN, a hydrofluoro- or perfluoro-alkyl radical, C1 to C6, and / or a radical C3-C10 cycloalkyl, and / or at least one cycloalkyl, aryl, he- radical terocyclic, CS to C18, optionally substituted, - with R4 and RS being able to represent, independently of each other, a hydrogen atom, or an alkyl, perfluoroalkyl or hydro- radical linear, saturated C1 to C30, preferably C3 to C12, fluoroalkyl, or unsaturated in C2 to C30, preferably in C3 to C12, or branched or cyclic, saturated or unsaturated, C3 to C30, preferably C4 to C12; or a C6 to C10 aryl radical, - X represents a radical chosen from -CO-, -CH(OH)-, -CH(NH;)-, preferentially a -CH(OH)- group; - S represents a monosaccharide or a polysaccharide comprising up to 20 sugar units, preferably up to 6 sugar units, in the form pyranose and / or furanose and of L and / or D series, said mono- or poly- saccharide which can be substituted by an obligatory hydroxyl group- torially free, and possibly one or more amine function(s) possibly protected, and - the S-CH,-X bond represents a C-anomeric bond, which can be a or PB, -as well as their physiologically acceptable salts, their solvates such as than hydrates and their isomers.

10. Use according to claim 8 or 9, wherein said C-glycoside is C-beta-D-xylopyranoside-2-hydroxy-propane.

11. | Use according to any one of claims 8 to 10, in which the mass ratio [C glycoside(s) / extract from the biomass of yeast of the species Aureobasidium pullulans] is less than or equal to 50, more preferably, the mass ratio [C-glycoside(s) / extract of the yeast biomass of the species Aureobasidium pullulans] is included between 5 and 50, even better between 8 and 49. |Claim 12] Composition, in particular cosmetic, non-therapeutic, comprising at least one cosmetic active ingredient comprising at least one extract yeast biomass of the species Aureobasidium pullulans, in particular as defined according to any one of claims 1 to 7 and at least one C-glycoside, in particular as defined according to the res- indications 9 and 10, in particular present in a mass ratio such that defined in claim 11.

13. Composition according to the preceding claim, wherein said extract is present in the composition in a content ranging from 0.0005% at 1% by weight of dry matter, preferably ranging from 0.001% to 1% by dry matter weight, more preferably ranging from 0.005% to 0.5% in weight of dry matter, and even better ranging from 0.01% to 0.3% in weight, relative to the total weight of the composition.

14. | A composition according to claim 12 or 13, wherein said C- glycoside is present in the composition in an amount ranging from 0.001 % to 10% by weight of active ingredient relative to the total weight of the com- position, preferably from 0.005% to 5% by weight of active material, plus preferably from 0.01% to 4% by weight of active material relative to to the total weight of the composition, even better from 0.5% to 3.5% by weight of active ingredient relative to the total weight of the composition, such that 0.6% or 3.2% by weight of active ingredient relative to the total weight of the composition.

15. Non-therapeutic cosmetic process for keratin materials comprising at least one step of application to said keratin materials tinics, preferably on the skin, of a composition as defined according to any one of claims 12 to 14.

16. Method according to claim 15, characterized in that it is intended to prevent and / or treat the signs of skin aging and / or strengthen and / or improve skin barrier function.

17. Method according to claim 15 or 16, characterized in that it is intended for skin hydration and / or improving the quality of the skin surface, especially improving skin radiance and / or improvement of the homogeneity of the complexion and / or reduction of microreliefs of the skin.